

CORRECTED VERSION

Rec'd PCT/PTO 02 OCT 2005

(19) World Intellectual Property Organization  
International Bureau



10/551840



(43) International Publication Date  
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number  
**WO 2004/087213 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 47/10, 38/24**

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, BE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
**PCT/EP2004/050432**

(22) International Filing Date: 2 April 2004 (02.04.2004)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

**Published:**

(26) Publication Language: English

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(30) Priority Data:

03100882.4	2 April 2003 (02.04.2003)	EP
03101543.1	27 May 2003 (27.05.2003)	EP
03101828.6	20 June 2003 (20.06.2003)	EP

(71) Applicant (for all designated States except US): **ARES TRADING S.A. [CH/CH]**; Zone Industrielle de l'Ournet-taz, CH-1170 Aubonne (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SAMARITANI, Fabrizio [IT/IT]**; Via Luigi Chiala 130, I-00139 Roma (IT). **DONATI, Piergiorgio [IT/CH]**; Rue de Lausanne 66, CH-1110 Morges (CH).

(74) Agent: **HASSA, Juergen**; Serono International SA, Intellectual Property, 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

(15) Information about Correction:  
see PCT Gazette No. 11/2005 of 17 March 2005, Section II

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2004/087213 A1

(54) Title: LIQUID PHARMACEUTICAL FORMULATIONS OF FSH AND LH TOGETHER WITH A NON-IONIC SURFACTANT

(57) Abstract: The invention relates to the field of pharmaceutical formulations of follicle -stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic <sup>®</sup> F77, Pluronic F87, Pluronic F88 and Pluronic F68.

(19) World Intellectual Property Organization  
International Bureau



Rec'd PCT/PTO 12 OCT 2005

(43) International Publication Date  
14 October 2004 (14.10.2004)

PCT



10/551840

(10) International Publication Number  
WO 2004/087213 A1

(51) International Patent Classification<sup>7</sup>: A61K 47/10, 38/24

(21) International Application Number: PCT/EP2004/050432

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03100882.4	2 April 2003 (02.04.2003)	EP
03101543.1	27 May 2003 (27.05.2003)	EP
03101828.6	20 June 2003 (20.06.2003)	EP

(71) Applicant (for all designated States except US): ARES TRADING S.A. [CH/CH]; Zone Industrielle de l'Ournietaz, CH-1170 Aubonne (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SAMARITANI, Fabrizio [IT/IT]; Via Luigi Chiala 130, I-00139 Roma (IT). DONATI, Piergiorgio [IT/CH]; Rue de Lausanne 66, CH-1110 Morges (CH).

(74) Agent: HASSA, Juergen; Serono International SA, Intellectual Property, 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/087213 A1

(54) Title: LIQUID PHARMACEUTICAL FORMULATIONS OF FSH AND LH TOGETHER WITH A NON-IONIC SURFACTANT

(57) Abstract: The invention relates to the field of pharmaceutical formulations of follicle -stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic <sup>®</sup> F77, Pluronic F87, Pluronic F88 and Pluronic F68.

**LIQUID PHARMACEUTICAL FORMULATIONS OF FSH AND LH TOGETHER WITH A NON-IONIC SURFACTANT**

**Field of Invention**

The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), formulations of luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH); as well as to methods of producing such formulations.

**Background of the Invention**

Follicle-stimulating hormone (FSH), luteinising hormone (LH) and chorionic gonadotrophin (CG) are injectable proteins falling into the class of gonadotrophins. FSH, LH and hCG are used alone and in combination in the treatment of infertility and reproductive disorders in both female and male patients.

In nature, FSH and LH are produced by the pituitary gland. For pharmaceutical use, FSH and LH and their variants may be produced recombinantly (rFSH and rLH), or they may be produced from the urine of postmenopausal women (uFSH and uLH).

FSH is used in female patients in ovulation induction (OI) and in controlled ovarian hyperstimulation (COH) for assisted reproductive technologies (ART). In a typical treatment regimen for ovulation induction, a patient is administered daily injections of FSH or a variant (about 75 to 300 IU FSH/day) for a period of from about 6 to about 12 days. In a typical treatment regimen for controlled ovarian hyperstimulation, a patient is administered daily injections of FSH or a variant (about 150-600 IU FSH/day) for a period of from about 6 to about 12 days.

FSH is also used to induce spermatogenesis in men suffering from oligospermia. A regimen using 150 IU FSH 3 times weekly in combination with 2'500 IU hCG twice weekly has been successful in achieving an improvement in sperm count in men suffering from hypogonadotropic hypogonadism <sup>1</sup>.

LH is used in female patients in combination with FSH in OI and in COH, particularly in those patients having very low endogenous LH levels or resistance to LH, such as women suffering from hypogonadotropic hypogonadism (HH, WHO group I) or older patients (i.e. 35 years or older), and patients in which embryo implantation or early miscarriage is a problem. LH in combination with FSH has traditionally been available in a preparation called human menopausal gonadotrophins (hMG)

extracted from the urine of postmenopausal women. hMG has a 1:1 ratio of FSH:LH activity.

CG acts at the same receptor as LH and elicits the same responses. CG has a longer circulation half-life than LH and is therefore commonly used as a long-acting source of LH-activity. CG is used in OI and COH regimens to mimic the natural LH peak and trigger ovulation. An injection of human chorionic gonadotrophin (hCG) is used to trigger ovulation at the end of stimulation with FSH or a mixture of FSH and LH. CG may also be used together with FSH during stimulation for OI and COH, in order to provide LH-activity during stimulation in patients in which LH-activity is desirable, such as those mentioned above.

FSH, LH and CG are members of the heterodimer, glycoprotein hormone family that also includes thyroid stimulating hormone (TSH). The members of this family are heterodimers, comprising an  $\alpha$ - and a  $\beta$ -subunit. The subunits are held together by noncovalent interactions. The human FSH (hFSH) heterodimer consists of (i) a mature 92 amino acid glycoprotein alpha subunit, which also is common to the other human family members (i.e., chorionic gonadotrophin ("CG"), luteinising hormone ("LH") and thyroid stimulating hormone ("TSH")); and (ii) a mature 111 amino acid beta subunit that is unique to FSH<sup>2</sup>. The human LH heterodimer consists of (i) the mature 92 amino acid glycoprotein alpha subunit; and (ii) a mature 112 beta subunit that is unique to LH<sup>3</sup>. The alpha and beta subunits of the glycoproteins may be prone to dissociate in formulations, due to interaction with a preservative, surfactant and other excipients. Dissociation of the subunits leads to loss of biological potency<sup>4</sup>.

FSH is formulated for intramuscular (IM) or subcutaneous (SC) injection. FSH is supplied in lyophilised (solid) form in vials or ampoules of 75 IU/vial and 150 IU/vial with a shelf life of one and a half to two years when stored at 2-25°C. A solution for injection is formed by reconstituting the lyophilised product with water for injection (WFI). For ovulation induction or controlled ovarian hyperstimulation, daily injections with starting doses of 75 IU to 600 IU are recommended for up to about ten days. Depending on the patient's response, up to three cycles of treatment with increasing doses of FSH can be used. With lyophilised formulations, the patient is required to reconstitute a new vial of lyophilised material with diluent and administer it immediately after reconstitution on a daily basis [Package insert N1700101A,

published in February 1996, for Fertinex™ (urofollitropin for injection, purified) for subcutaneous injection, by Serono Laboratories, Inc., Randolph, MA].

FSH has also been formulated in both single-dose and multi-dose liquid formats, in vials, or ampoules. Single dose formats must remain stable and potent in storage prior to use. Multi-dose formats must not only remain stable and potent in storage prior to use, but must also remain stable, potent and relatively free of bacteria over the multiple-dose use regimen administration period, after the seal of the ampoule has been compromised. For this reason, multi-dose formats often contain a bacteriostatic agent.

10

LH is formulated for intramuscular (IM) or subcutaneous (SC) injection. LH is supplied in lyophilised (solid) form in vials or ampoules of 75 IU/vial with a shelf life of one and a half to two years when stored at 2-25°C. A solution for injection is formed by reconstituting the lyophilised product with water for injection (WFI). For ovulation induction or controlled ovarian hyperstimulation, in conjunction with FSH, daily injections with starting doses of 75 IU to 600 IU LH are recommended for up to about ten days.

EP 0 618 808 (Applied Research Systems ARS Holding N.V.) discloses a pharmaceutical composition comprising a solid intimate mixture of gonadotrophin and a stabilising amount of sucrose alone or in combination with glycine.

EP 0 814 841 (Applied Research Systems ARS Holding N.V.) discloses a stable, liquid pharmaceutical composition comprising recombinant human chorionic gonadotrophin (hCG) and a stabilizing amount of mannitol.

EP 0 448 146 (AKZO N.V.) discloses a stabilized gonadotrophin containing lyophilisate comprising one part by weight of a gonadotrophin; and 200 to 10,000 parts by weight of a dicarboxylic acid salt stabilizer associated with the gonadotrophin.

EP 0 853 945 (Akzo Nobel N.V.) discloses a liquid gonadotrophin-containing formulation characterised in that the formulation comprises a gonadotrophin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound.

WO 00/04913 (Eli Lilly and Co.) discloses a formulation comprising FSH or an FSH variant, containing an alpha and beta subunit, and a preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an aqueous diluent.

There remains a need for stable liquid formulations of FSH or FSH variants, and mixtures of FSH and LH, either for single dose or multiple dose administration.

10

**Summary of the invention**

It is an object of the invention to provide new freeze dried as well as liquid formulations of FSH or FSH variants, LH or LH variants, to provide methods for their preparation, and methods for their pharmaceutical or veterinary use in the treatment of fertility disorders.

15

It is a further object of the invention to provide new freeze dried and liquid formulations of mixtures of FSH and LH, to provide methods for their preparation, and methods for their pharmaceutical or veterinary use in the treatment of fertility disorders.

20

In a first aspect, the invention provides a freeze dried and liquid pharmaceutical composition comprising FSH or a variant thereof, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

25

In a second aspect, the invention provides a method for manufacturing a liquid pharmaceutical composition comprising forming a solution of FSH or a variant thereof, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68 and WFI.

30

In a third aspect, the invention provides a method for manufacturing a packaged pharmaceutical composition comprising dispensing a solution comprising FSH, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide,

35

preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, into a container.

5 In a fourth aspect, the invention provides an article of manufacture for human pharmaceutical use, comprising a vial comprising a solution of FSH or an FSH variant, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68 and written material stating that such solution may be held over a period of at or about twenty-four hours or greater after the first use.

10 10 In a fifth aspect, the invention provides a freeze dried and liquid pharmaceutical composition comprising FSH and LH, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

15 15 In a sixth aspect, the invention provides a method for manufacturing a freeze dried and liquid pharmaceutical composition comprising forming a solution of FSH and LH and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

20 20 In an seventh aspect, the invention provides a method for manufacturing a packaged pharmaceutical composition comprising dispensing a solution comprising FSH and LH, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, into a container.

25 30 In an eighth aspect, the invention provides an article of manufacture for human pharmaceutical use, comprising a vial comprising a solution of FSH and LH, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68 and written material stating that such solution may be held over a period of at or about twenty-four hours or greater after the first use.

35 35 In a ninth aspect, the invention provides an article of manufacture for human pharmaceutical use, comprising a first container comprising freeze dried FSH or an

FSH variant, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68 and a second container comprising a solvent for reconstitution, preferably an aqueous solution containing a bacteriostatic, preferably m-cresol.

5

In an tenth aspect, the invention provides an article of manufacture for human pharmaceutical use, comprising a first container comprising freeze dried LH or an LH variant, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic

10

F68 and a second container comprising a solvent for reconstitution, preferably an aqueous solution containing a bacteriostatic, preferably m-cresol.

In an eleventh aspect, the invention provides an article of manufacture for human pharmaceutical use, comprising a first container comprising freeze dried FSH as well

15

as LH or an FSH or LH variant variant, and a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68 and a second container comprising a solvent for reconstitution, preferably an aqueous solution with m-cresol.

20 **Detailed description of the Invention**

**Brief description of the drawings**

Figure 1 shows the percentage of oxidised  $\alpha$ -subunit in formulations of FSH containing Pluronic F68, methionine at 10  $\mu\text{g/ml}$  ("Meth 10  $\mu\text{g/ml}$ ") and 100  $\mu\text{g/ml}$  ("Meth 100  $\mu\text{g/ml}$ ") versus a formulation with no methionine ("No methionine"), at time 0, 1 week and 2 weeks.

The liquid and freeze dried FSH or FSH and LH formulations of the Invention have improved or more suitable properties or stability, and are useful for infertility treatment in women and/or men. These formulations and articles of manufacture are

30

additionally suitable for use in injectable and alternative delivery systems, e.g., but not limited to, nasal, pulmonary, transmucosal, transdermal, oral, subcutaneous, intramuscular or parenteral sustained release. In a particularly preferred embodiment the formulations of the Invention are for subcutaneous and/or intramuscular injection. The FSH or FSH and LH variant solutions and formulations

35

provided may also have increased *in vivo* potency over time compared to known commercial products, by preventing or reducing loss of activity or stability, or by

improving any aspect of the effectiveness or desirability of administration, e.g., by at least one of mode, frequency, dosage, comfort, ease of use, biological activity *in vitro* or *in vivo*, and the like.

5     Follicle stimulating hormone, or FSH, as used herein refers to the FSH produced as a full-length mature protein which includes, but is not limited to human FSH or "hFSH", whether produced recombinantly or isolated from human sources, such as the urine of postmenopausal women. The protein sequence of the human glycoprotein alpha subunit is provided in SEQ ID NO: 1, and the protein sequence of the human FSH  
10    beta subunit is given in SEQ ID NO:2.

The expression "FSH variant" is meant to encompass those molecules differing in amino acid sequence, glycosylation pattern or in inter-subunit linkage from human FSH but exhibiting FSH-activity. Examples include CTP-FSH, a long-acting modified  
15    recombinant FSH, consisting of the wild type  $\alpha$ -subunit and a hybrid  $\beta$ -subunit in which the carboxy terminal peptide of hCG has been fused to the C-terminal of the  $\beta$ -subunit of FSH, as described in LaPolt *et al.*; Endocrinology; 1992, 131, 2514-2520; or Klein *et al.*; Development and characterization of a long-acting recombinant hFSH agonist; Human Reprod. 2003, 18, 50-56]. Also included is single chain CTP-  
20    FSH, a single chain molecule, consisting of the following sequences (from N-terminal to C-terminal):

$\beta$ FSH	$\beta$ hCG-CTP(113-145)	$\alpha$ FSH
-------------	--------------------------	--------------

25    wherein  $\beta$ FSH signifies the  $\beta$ -subunit of FSH,  $\beta$ hCG CTP (113-145) signifies the carboxy terminal peptide of hCG and  $\alpha$ FSH signifies the  $\alpha$ -subunit of FSH, as described by Klein *et al.*<sup>5</sup> Other examples of FSH variants include FSH molecules having additional glycosylation sites incorporated in the  $\alpha$ - and/or  $\beta$ -subunit, as disclosed in WO 01/58493 (Maxygen), particularly as disclosed in claims 10 and 11  
30    of WO 01/58493, and FSH molecules with intersubunit S-S bonds, as disclosed in WO 98/58957.

The FSH variants referred to herein also include the carboxy terminal deletions of the beta subunit that are shorter than the full length mature protein of SEQ ID NO:2.  
35    Carboxy terminal deletions of the human beta subunit are provided in SEQ IDS NOS:

3, 4, and 5. It is understood that the carboxy terminal variants of the beta chain form dimers with a known alpha subunit to form an FSH variant heterodimer.

FSH heterodimers or FSH variant heterodimers can be produced by any suitable  
5 method, such as recombinantly, by isolation or purification from natural sources as  
may be the case, or by chemical synthesis, or any combination thereof.

The use of the term "recombinant" refers to preparations of FSH, LH or FSH and LH  
10 variants that are produced through the use of recombinant DNA technology (see for  
example WO 85/01958). The sequences for genomic and cDNA clones of FSH are  
known for the alpha and beta subunits of several species<sup>6</sup>. One example of a  
15 method of expressing FSH or LH using recombinant technology is by transfection of  
eukaryotic cells with the DNA sequences encoding an alpha and beta subunit of FSH  
or LH, whether provided on one vector or on two vectors with each subunit having a  
separate promoter, as described in European patent nos. EP 0 211 894 and EP 0  
15 487 512. Another example of the use of recombinant technology to produce FSH or  
LH is by the use of homologous recombination to insert a heterologous regulatory  
segment in operative connection to endogenous sequences encoding the subunits of  
FSH or LH, as described in European patent no. EP 0 505 500 (Applied Research  
20 Systems ARS Holding NV).

The FSH or FSH variant used in accordance with the present invention may be  
produced not only by recombinant means, including from mammalian cells, but also  
may be purified from other biological sources, such as from urinary sources.

25 Acceptable methodologies include those described in Hakola, K. Molecular and  
Cellular Endocrinology, 127:59-69, 1997; Keene, et al., J. Biol. Chem., 264:4769-  
4775, 1989; Cerpa-Poljak, et al., Endocrinology, 132:351-356, 1993; Dias, et al., J.  
Biol. Chem., 269:25289-25294, 1994; Flack, et al., J. Biol. Chem., 269:14015-14020,  
1994; and Valove, et al., Endocrinology, 135:2657-2661, 1994, U.S. Patent  
30 3,119,740 and US Patent no. 5,767,067.

35 Luteinising hormone, or LH, as used herein refers to the LH produced as a full -length  
mature protein, which includes, but is not limited to human LH or "hLH", whether  
produced recombinantly or isolated from human sources, such as the urine of  
postmenopausal women. The protein sequence of the human glycoprotein alpha

subunit is provided in SEQ ID NO: 1, and the protein sequence of the human LH beta subunit<sup>7</sup> is given in SEQ ID NO: 6. In a preferred embodiment the LH is recombinant.

5 The expression "LH variant" is meant to encompass those molecules differing in amino acid sequence, glycosylation pattern or in inter-subunit linkage from human LH but exhibiting LH-activity.

10 LH heterodimers or LH variant heterodimers can be produced by any suitable method, such as recombinantly, by isolation or purification from natural sources as may be the case, or by chemical synthesis, or any combination thereof.

15 The term "administer" or "administering" means to introduce a formulation of the present invention into the body of a patient in need thereof to treat a disease or condition.

15 The term "patient" means a mammal that is treated for a disease or condition. Patients are of, but not limited to, the following origin, human, ovine, porcine, equine, bovine, rabbit and the like.

20 The term "potency" in relation to FSH activity, refers to the ability of an FSH formulation or a mixed formulation, to elicit biological responses associated with FSH, such as ovarian weight gain in the Steelman-Pohley assay<sup>8</sup>, or follicular growth in a female patient. Follicular growth in a female patient can be evaluated by ultrasound, for example, in terms of the number of follicles having a mean diameter of at or about 16 mm on day 8 of stimulation. Biological activity is evaluated with respect to an accepted standard for FSH.

25 The term "potency" in relation to LH activity, refers to the ability of an LH formulation or a mixed formulation, to elicit biological responses associated with LH, such as seminal vesicle weight gain method.<sup>9</sup> Biological activity of LH is evaluated with respect to an accepted standard for LH.

30 The term "aqueous diluent" refers to a liquid solvent that contains water. Aqueous solvent systems may consist solely of water, or may consist of water plus one or more miscible solvents, and may contain dissolved solutes such as sugars, buffers, salts or other excipients. The more commonly used non-aqueous solvents are the

short-chain organic alcohols, such as, methanol, ethanol, propanol, short-chain ketones, such as acetone, and poly alcohols, such as glycerol.

An "isotonicity agent" is a compound that is physiologically tolerated and imparts a suitable tonicity to a formulation to prevent the net flow of water across cell membranes that are in contact with the formulation. Compounds such as glycerin, are commonly used for such purposes at known concentrations. Other suitable isotonicity agents include, but are not limited to, amino acids or proteins (e.g., glycine or albumin), salts (e.g., sodium chloride), and sugars (e.g., dextrose, sucrose and lactose).

The term "bacteriostatic" or "bacteriostatic agent" refers to a compound or compositions added to a formulation to act as an anti-bacterial agent. A preserved FSH or FSH variant or FSH and LH containing formulation of the present invention preferably meets statutory or regulatory guidelines for preservative effectiveness to be a commercially viable multi-use product, preferably in humans. Examples of bacteriostatics include phenol, *m*-cresol, *p*-cresol, *o*-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal.

The term "buffer" or "physiologically-acceptable buffer" refers to solutions of compounds that are known to be safe for pharmaceutical or veterinary use in formulations and that have the effect of maintaining or controlling the pH of the formulation in the pH range desired for the formulation. Acceptable buffers for controlling pH at a moderately acidic pH to a moderately basic pH include, but are not limited to, such compounds as phosphate, acetate, citrate, arginine, TRIS, and histidine. "TRIS" refers to 2-amino-2-hydroxymethyl-1,3-propanediol, and to any pharmacologically acceptable salt thereof. Preferable buffers are phosphate buffers with saline or an acceptable salt.

The term "phosphate buffer" refers to solutions containing phosphoric acid or salts thereof, adjusted to a desired pH. Generally phosphate buffers are prepared from phosphoric acid, or a salt of phosphoric acid, including but not limited to sodium and potassium salts. Several salts of phosphoric acid are known in the art, such as sodium and potassium monobasic, dibasic, and tribasic salts of the acid. Salts of phosphoric acid are also known to occur as hydrates of the occurring salt. Phosphate

buffers may cover a range of pHs, such as from about pH 4 to about pH 10, and preferred ranges from about pH 5 to about pH 9, and a most preferred range of at or about 6.0 to at or about 8.0, most preferably at or about pH 7.0.

5 The term "vial" refers broadly to a reservoir suitable for retaining FSH in solid or liquid form in a contained sterile state. Examples of a vial as used herein include ampoules, cartridges, blister packages, or other such reservoir suitable for delivery of the FSH to the patient via syringe, pump (including osmotic), catheter, transdermal patch, pulmonary or transmucosal spray. Vials suitable for packaging products for  
10 parenteral, pulmonary, transmucosal, or transdermal administration are well known and recognized in the art.

The term "stability" refers to the physical, chemical, and conformational stability of FSH and LH in the formulations of the present invention (including maintenance of biological potency). Instability of a protein formulation may be caused by chemical degradation or aggregation of the protein molecules to form higher order polymers, by dissociation of the heterodimers into monomers, deglycosylation, modification of glycosylation, oxidation (particularly of the  $\alpha$ -subunit) or any other structural modification that reduces at least one biological activity of an FSH polypeptide  
15 included in the present invention.  
20

A "stable" solution or formulation, is one wherein the degree of degradation, modification, aggregation, loss of biological activity and the like, of proteins therein is acceptably controlled, and does not increase unacceptably with time. Preferably the formulation retains at least at or about 80% of the labelled FSH activity and at least at or about 80% of the labelled LH activity over a period of 6 months at a temperature of  
25 at or about 2-8°C, more preferably at or about 2-8°C, more preferably at or about 4-5°C. FSH activity can be measured using the Steelman-Pohley ovarian weight gain bioassay<sup>5</sup>. LH activity can be measured using the seminal vesicle weight gain  
30 bioassay<sup>10</sup>.

The term "treating" refers to the administration, follow up, management and/or care of a patient for which FSH and/or LH administration is desirable for the purpose of follicle or testicular stimulation or any other physiological response regulated by FSH and/or LH. Treating can thus include, but is not limited to, the administration of FSH and/or LH for the induction or improvement of sperm quality, stimulation of  
35

testosterone release in the male, or follicular development or for ovulation induction in the female.

The expression "multi-dose use" is intended to include the use of a single vial, ampoule or cartridge of an FSH formulation or a formulation of FSH and LH for more than one injection, for example 2, 3, 4, 5, 6 or more injections. The injections are preferably made over a period of at least at or about 12 hours, 24 hours, 48 hours, etc., preferably up to a period of at or about 12 days. The injections may be spaced in time, for example, by a period of 6, 12, 24, 48 or 72 hours.

10

A "salt" of a protein is an acid or base addition salt. Such salts are preferably formed between any one or more of the charged groups in the protein and any one or more physiologically acceptable, non-toxic cations or anions. Organic and inorganic salts include, for example, those prepared from acids such as hydrochloric, sulphuric, sulfonic, tartaric, fumaric, hydrobromic, glycolic, citric, maleic, phosphoric, succinic, acetic, nitric, benzoic, ascorbic, p-toluenesulfonic, benzenesulfonic, naphthalenesulfonic, propionic, carbonic, and the like, or for example, ammonium, sodium, potassium, calcium, or magnesium.


15

The inventors have found that by formulating FSH and mixtures of FSH and LH with a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic® F68, particularly preferably Pluronic F68 (BASF, Pluronic F68 is also known as Poloxamer 188) they obtain stable formulations that minimise the loss of active principle (FSH or FSH and LH) caused by adsorption on the surfaces of the vial and/or delivery device (e.g. syringe, pump, catheter, etc.).

20

The inventors have further found that by formulating FSH and mixtures of FSH and LH with a surfactant selected from block copolymers of ethylene oxide and propylene oxide, preferably Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic® F68, particularly preferably Pluronic F68 (BASF, Pluronic F68 is also known as Poloxamer 188) they obtain a stable formulation that avoids the problem of precipitation in the presence of a bacteriostatic agent, such as *m*-cresol and phenol. Precipitation, resulting in the formation of turbid or milky solutions occurs when TWEEN 20 is used with *m*-cresol or phenol.

The Pluronic surfactants are block copolymers of ethylene oxide (EO) and propylene oxide (PO). The propylene oxide block (PO) is sandwiched between two ethylene oxide (EO) blocks.



5

Pluronic surfactants are synthesised in a two-step process:

1. A hydrophobe of the desired molecular weight is created by the controlled addition of propylene oxide to the two hydroxyl groups of propylene glycol; and
- 10 2. Ethylene oxide is added to sandwich the hydrophobe between hydrophilic groups.

In Pluronic® F77, the percentage of polyoxyethylene (hydrophile) is 70%, and the molecular weight of the hydrophobe (polyoxypropylene) is approximately 2,306 Da.

15 In Pluronic F87, the percentage of polyoxyethylene (hydrophile) is 70%, and the molecular weight of the hydrophobe (polyoxypropylene) is approximately 2,644 Da.

In Pluronic F88, the percentage of polyoxyethylene (hydrophile) is 80%, and the molecular weight of the hydrophobe (polyoxypropylene) is approximately 2,644 Da.

20 In Pluronic F68, the percentage of polyoxyethylene (hydrophile) is 80%, and the molecular weight of the hydrophobe (polyoxypropylene) is approximately 1,967 Da.

Typical properties of Pluronic F77 are listed below.

Average Molecular Weight: 6600;

25 Melt/pour point: 48 °C ;  
Physical Form @ 20°C : solid;  
Viscosity (Brookfield) cps: 480 [liquids at 25 °C, pastes at 60 °C and solids at 77 °C];  
Surface tension, dynes/cm @ 25°C;  
0.1% Conc. : 47.0  
30 0.01% Conc. : 49.3  
0.001% Conc.: 52.8  
Interfacial tension, dynes/cm @ 25°C vs. Nujol;  
0.1% Conc. : 17.7  
0.01% Conc. : 20.8  
35 0.001% Conc. : 25.5

Draves Wetting, Seconds 25°C  
1.0% Conc.: > 360  
0.1% Conc.: > 360

Foam Height  
5      Ross Miles, 0.1%, mm @ 50°C: 100  
         Ross Miles, 0.1%, mm @ 26°C: 47  
         Dynamic, 0.1%, mm @ 400 ml/min: > 600

Cloud point in aqueous solution, °C  
10     1% Conc.: >100  
      10% Conc.: >100

HLB (hydrophile-lipophile balance): 25

Typical properties of Pluronic F87 are listed below:  
Average Molecular Weight: 7700;  
15    Melt/pour point: 49°C ;  
Physical Form @ 20°C : solid;  
Viscosity (Brookfield) cps: 700 [liquids at 25°C, pastes at 60°C and solids at 77°C];  
Surface tension, dynes/cm @ 25°C;  
0.1% Conc. : 44.0

20    0.01% Conc. : 47.0  
      0.001% Conc.: 50.2

Interfacial tension, dynes/cm @ 25°C vs Nujol;  
0.1% Conc. : 17.4  
0.01% Conc. : 20.3

25    0.001% Conc. : 23.3

Draves Wetting, Seconds 25°C  
30    1.0% Conc.: > 360  
      0.1% Conc.: > 360

Foam Height  
30    Ross Miles, 0.1%, mm @ 50°C: 80  
         Ross Miles, 0.1%, mm @ 26°C: 37  
         Dynamic, 0.1%, mm @ 400 ml/min: > 600

Cloud point in aqueous solution, °C  
35    1% Conc.: >100  
      10% Conc.: >100

HLB (hydrophile-lipophile balance): 24

Typical properties of Pluronic F88 are listed below:  
Average Molecular Weight: 11400;  
40    Melt/pour point: 54°C ;  
Physical Form @ 20°C : solid;  
Viscosity (Brookfield) cps: 2300 [liquids at 25°C, pastes at 60°C and solids at 77°C];  
Surface tension, dynes/cm @ 25°C;  
0.1% Conc. : 48.5

45    0.01% Conc. : 52.6  
      0.001% Conc.: 55.7

Interfacial tension, dynes/cm @ 25°C vs Nujol;  
0.1% Conc. : 20.5  
0.01% Conc. : 23.3

50    0.001% Conc. : 27.0

Draves Wetting, Seconds 25°C  
50    1.0% Conc.: > 360  
      0.1% Conc.: > 360

Foam Height

Ross Miles, 0.1%, mm @ 50°C: 80  
Ross Miles, 0.1%, mm @ 26°C: 37  
Dynamic, 0.1%, mm @ 400 ml/min: > 600  
Cloud point in aqueous solution, °C  
5           1% Conc.: >100  
            10% Conc.: >100  
HLB (hydrophile-lipophile balance): 28

Typical properties of Pluronic F68 are listed below.  
10 Average Molecular Weight: 8400;  
Melt/pour point: 52°C ;  
Physical Form @ 20°C : solid;  
Viscosity (Brookfield) cps: 1000 [liquids at 25°C, pastes at 60°C and solids at 77°C];  
Surface tension, dynes/cm @ 25°C;  
15           0.1% Conc. : 50.3  
            0.01% Conc. : 51.2  
            0.001% Conc.: 53.6  
Interfacial tension, dynes/cm @ 25°C vs Nujol;  
20           0.1% Conc. : 19.8  
            0.01% Conc. : 24.0  
            0.01% Conc. : 26.0  
Drave's Wetting, Seconds 25°C  
25           1.0% Conc.: > 360  
            0.1% Conc.: > 360  
Foam Height  
Ross Miles, 0.1%, mm @ 50°C: 35  
Ross Miles, 0.1%, mm @ 26°C: 40  
Dynamic, 0.1%, mm @ 400 ml/min: > 600  
Cloud point in aqueous solution, °C  
30           1% Conc.: >100  
            10% Conc.: >100  
HLB (hydrophile-lipophile balance): 29

Other polymers having properties similar to those listed above may also be used in  
35 the formulations of the invention. The preferred surfactant is Pluronic F68, and  
surfactants having similar properties.

Pluronic, particularly Pluronic F68, is preferably present in the formulation at a  
concentration that is sufficient to maintain FSH and/or LH stability over the desired  
40 storage period (for example 6 to 12 to 24 months), and also at a concentration that is  
sufficient to prevent protein losses due to adsorption on surfaces, such as the vial,  
ampoule or cartridge or the syringe.

Preferably the concentration of Pluronic, particularly Pluronic F68, in liquid  
formulations is at or about 0.01 mg/ml to at or about 1 mg/ml, more preferably at or  
45 about 0.05 mg/ml to at or about 0.5 mg/ml, more particularly preferably at or about  
0.2 mg/ml to at or about 0.4 mg/ml, most preferably at or about 0.1 mg/ml.

The follicle-stimulating hormone (FSH) within the freeze-dried formulation is preferably present at a concentration (w/w) of at or about 0.1 to 10 µg/mg of the total formulation. In one embodiment, the follicle-stimulating hormone (FSH) is present at 5 a concentration of at or about 0.3 to 5 µg/mg of the total formulation. In a further embodiment the follicle-stimulating hormone (FSH) is present at a concentration of at or about 0.37 to 2 µg/mg of the total formulation.

The luteinising hormone (LH) within the freeze-dried formulation is preferably present 10 at a concentration of at or about 0.1 to 3 µg/mg of the total formulation. In one embodiment, the luteinising hormone (LH) is present at a concentration of at or about 0.1 to 1 µg/mg of the total formulation. In a further embodiment, the luteinising hormone (LH) is present at a concentration of at or about 0.1 to 0.6 µg/mg of the total formulation.

15 In the liquid formulations – including the reconstituted formulations - comprising FSH, preferably the concentration of FSH in the formulation is at or about 150 IU/ml to at or about 2,000 IU/ml, more preferably at or about 300 IU/ml to at or about 1,500 IU/ml, more particularly preferably at or about 450 to at or about 750, most preferably at or 20 about 600 IU/ml.

In the liquid formulations – including the reconstituted formulations - comprising LH, 25 preferably the LH concentration in the formulation is at or about 50 IU/ml to at or about 2,000 IU/ml, more preferably at or about 150 to at or about 1,500 IU/ml, more particularly preferably at or about 300 IU/ml to at or about 750 IU/ml, particularly preferably 625 IU/ml.

In formulations comprising both FSH and LH, the ratio of FSH to LH (FSH:LH, IU:IU, 30 FSH measured with rat ovarian weight gain assay and LH measured with rat seminal vesicle weight gain assay) is preferably within the range of at or about 6:1 to at or about 1:6, more preferably at or about 4:1 to at or about 1:2, more particularly preferably at or about 3:1 to at or about 1:1. Particularly preferred ratios are 1:1 and 2:1.

In the freeze dried formulations, the surfactant, e.g. Pluronic F 68, is preferably 35 present at a concentration of at or about 0.001 to at or about 0.1 mg per mg of the total formulation, more preferably at or about 0.01 to at or about 0.075 mg/mg.

Preferably the concentration of Pluronic, particularly Pluronic F68, in the reconstituted formulations is at or about 0.01 mg/ml to at or about 1 mg/ml, more preferably at or about 0.05 mg/ml to at or about 0.5 mg/ml, more particularly preferably at or about 0.2 mg/ml to at or about 0.4 mg/ml, most preferably at or about 5  
0.1 mg/ml.

Preferably the FSH and LH are produced recombinantly, particularly preferably they are produced in Chinese hamster ovary cells transfected with a vector or vectors comprising DNA coding for the human glycoprotein alpha-subunit and the beta-subunit of FSH or LH. DNA encoding the alpha and beta-subunits may be present 10 on the same or different vectors.

Recombinant FSH and LH have several advantages over their urinary counterparts. Culture and isolation techniques using recombinant cells permit consistency between batches. In contrast, urinary FSH and LH vary greatly from batch to batch in such 15 characteristics as purity, glycosylation pattern, sialylation and oxidation of the subunits. Due to greater batch-to-batch consistency and purity of recombinant FSH and LH, the hormones can be readily identified and quantified using techniques such as isoelectric focussing (IEF). The ease with which recombinant FSH and LH can be identified and quantified permits the filling of vials by mass of hormone (fill-by-mass) 20 rather than filling by bioassay.

Preferably formulations of FSH of the present invention have pH between at or about 6.0 and at or about 8.0, more preferably at or about 6.8 to at or about 7.8, including about pH 7.0, pH 7.2, and 7.4. A preferred buffer is phosphate, with preferred 25 counterions being sodium or potassium ions. Phosphate saline buffers are well known in the art, such as Dulbecco's Phosphate buffered saline. Buffer concentrations in total solution can vary between at or about 5mM, 9.5mM, 10mM, 50mM, 100mM, 150mM, 200mM, 250mM, and 500mM. Preferably the buffer concentration is at or about 10mM. Particularly preferred is a buffer 10 mM in 30 phosphate ions with a pH of 7.0.

Preferably formulations of mixtures of FSH and LH of the present invention have pH between at or about 6.0 and at or about 9.0, more preferably at or about 6.8 to at or about 8.5, including about pH 7.0, pH 8.0, and 8.2, most preferably at or about pH 35 8.0.

The invention is directed to liquid formulations as well as freeze dried (lyophilised) formulations that may be reconstituted, in which the solvent (also for reconstitution) is water for injection. Liquid formulations may be single dose or multi-dose. Those liquid as well as freeze dried FSH and/or LH formulations of the invention that are intended for multi-dose use preferably comprise a bacteriostatic, such as phenol, *m*-cresol, *p*-cresol, *o*-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl, ethyl, propyl, butyl and the like), thymol, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal. Particularly preferred are phenol, benzyl alcohol and *m*-cresol, more preferred are phenol and *m*-cresol, most preferred is *m*-cresol. The bacteriostatic agent is used in an amount that will yield a concentration that is effective to maintain the formulation essentially bacteria free (suitable for injection) over the multi-dose injection period, which may be at or about 12 or 24 hours to at or about 12 or 14 days, preferably at or about 6 to at or about 12 days. The bacteriostatic is preferably present in a concentration of at or about 0.1% (mass bacteriostatic/mass of solvent) to at or about 2.0%, more preferably at or about 0.2% to at or about 1.0%. In the case of benzyl alcohol, particularly preferred is a concentration of 0.9%. In the case of phenol, particularly preferred is at or about 0.5%. In the case of *m*-cresol, particularly preferred is a concentration of at or about 0.3 % (e.g. at or about 3 mg/ml in WFI).

In a preferred embodiment, the invention provides a liquid pharmaceutical composition, preferably for multi-dose use, comprising FSH or a variant thereof, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from *m*-cresol and phenol, preferably *m*-cresol.

In a further preferred embodiment, the invention provides a liquid pharmaceutical composition, preferably for multi-dose use, comprising LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from *m*-cresol and phenol, preferably *m*-cresol.

In a further preferred embodiment, the invention provides a liquid pharmaceutical composition, preferably for multi-dose use, comprising FSH and LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from *m*-cresol and phenol, preferably *m*-cresol. Preferably the FSH and LH are present in a ratio (FSH:LH) of at or about 2:1 to at or about 1:1.

In a further preferred embodiment, the invention provides a method for manufacturing a liquid pharmaceutical composition, preferably for multi-dose use, comprising forming an aqueous solution of FSH or a variant thereof, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol, and WFI.

5

In a further preferred embodiment, the invention provides a method for manufacturing a liquid pharmaceutical composition, preferably for multi-dose use, comprising forming an aqueous solution of LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol, and WFI.

10

In a further preferred embodiment, the invention provides a method for manufacturing a liquid pharmaceutical composition, preferably for multi-dose use, comprising forming an aqueous solution of FSH and LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol, and WFI.

15

In yet another preferred embodiment, the invention provides a method for manufacturing a packaged pharmaceutical composition comprising dispensing a solution comprising FSH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol.

20

25

In yet another preferred embodiment, the invention provides a method for manufacturing a packaged pharmaceutical composition comprising dispensing a solution comprising FSH and LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol.

30

35

In yet another preferred embodiment, the invention provides an article of manufacture for human pharmaceutical use, comprising a vial comprising a solution of FSH or an FSH variant, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol, and written material stating that such solution may be held over a period of at or about twenty-four hours or greater after the first use.

Preferably the written material states that the solution may be held up to at or about 12 or 14 days after the first use.

In yet another preferred embodiment, the invention provides an article of manufacture for human pharmaceutical use, comprising a vial comprising a solution of FSH and LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol, and written material stating that such solution may be held over a period of at or about twenty-four hours or greater after the first use. Preferably the written material states that the solution may be held up to at or about 12 or 14 days after the first use.

In a particularly preferred embodiment, the formulation comprises m-cresol and Pluronic F68. The inventors have surprisingly found that formulations comprising Pluronic F68 do not precipitate in the presence of m-cresol, a problem observed with other surfactants.

Before the first use, that is before the seal of the vial ampoule or cartridge has been broken, the formulations of the invention may be kept for at least at or about 6 months, 12 months or 24 months. Under preferred storage conditions, before the first use, the formulations are kept away from bright light (preferably in the dark), at temperatures of at or about 2-8°C, more preferably at or about 4-5°C.

In a specific embodiment, the invention provides a freeze dried formulation for reconstitution, preferably for multi-dose use, comprising FSH or a variant thereof and a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, preferably Pluronic F 68.

In a further specific embodiment, the invention provides a freeze dried formulation for reconstitution, preferably for multi-dose use, comprising LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, preferably Pluronic F68.

In a further specific embodiment, the invention provides a freeze dried formulation, preferably for multi-dose use, comprising FSH and LH, a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, preferably Pluronic F68.

Preferably the FSH and LH are present in a ratio (FSH:LH) of at or about 2:1 to at or about 1:1.

In a further specific embodiment, the invention provides a method for manufacturing  
5 a freeze dried formulation, preferably for multi-dose use after reconstitution,  
comprising forming a mixture of FSH or a variant thereof with a surfactant selected  
from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and subjecting  
said mixture to lyophilisation.

10 In a further specific embodiment, the invention provides a method for manufacturing  
a freeze dried formulation, preferably for multi-dose use after reconstitution,  
comprising forming a mixture of LH with a surfactant selected from Pluronic® F77,  
Pluronic F87, Pluronic F88 and Pluronic F68, and subjecting said mixture to  
lyophilisation.

15 In a further specific embodiment, the invention provides a method for manufacturing  
a freeze dried formulation, preferably for multi-dose use after reconstitution,  
comprising forming a mixture of FSH and LH as well as a surfactant selected from  
Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and subjecting said  
mixture to lyophilisation.

20 In yet another preferred embodiment, the invention provides a method for  
manufacturing a packaged pharmaceutical composition comprising dispensing a  
freeze dried mixture comprising FSH and a surfactant selected from Pluronic® F77,  
25 Pluronic F87, Pluronic F88 and Pluronic F68.

In yet another preferred embodiment, the invention provides a method for  
manufacturing a packaged pharmaceutical composition comprising dispensing a  
freeze dried mixture comprising LH and a surfactant selected from Pluronic® F77,  
30 Pluronic F87, Pluronic F88 and Pluronic F68 into a container.

In yet another preferred embodiment, the invention provides a method for  
manufacturing a packaged pharmaceutical composition comprising dispensing a  
freeze dried mixture comprising FSH as well as LH and a surfactant selected from  
35 Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68 into a container.

In yet another preferred embodiment, the invention provides an article of manufacture for human pharmaceutical use, comprising a first container or vial comprising freeze dried FSH or an FSH variant and a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68. A second container or vial contains a diluent for reconstitution, preferably water and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol.

5 In yet another preferred embodiment, the invention provides an article of manufacture for human pharmaceutical use, comprising a first container or vial comprising freeze dried LH or an LH variant and a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68. A second container or vial contains a diluent for reconstitution, preferably water and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol.

10 15 In yet another preferred embodiment, the invention provides an article of manufacture for human pharmaceutical use, comprising a first container or vial comprising freeze dried FSH or an FSH variant as well as LH or an LH variant and a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68. A second container or vial contains a diluent for reconstitution, preferably water and a bacteriostatic selected from m-cresol and phenol, preferably m-cresol.

20

25 In a particularly preferred embodiment, the solvent for reconstitution comprises *m*-cresol. The inventors have found that freeze dried formulations comprising Pluronic F68 do not precipitate when reconstituted with a diluent containing *m*-cresol, a problem observed with other surfactants, e.g. Tween.

30 The freeze dried formulations of the invention may be kept for at least at or about 6 months, 12 months or 24 months. Under preferred storage conditions, before the first use, the formulations are kept away from bright light (preferably in the dark), at temperatures of at or about 25, preferably of at or about 2-8°C, more preferably at or about 4-5°C.

35 After the first use of a liquid or a reconstituted multi-dose formulation it may be kept and used for at least at or about 24 hours, preferably at least at or about 4, 5 or 6 days, more preferably for up to 12 or 14 days. After the first use the formulation is preferably stored at below room temperature (i.e. below at or about 25°C), more

preferably below at or about 10°C, more preferably at or about 2-8°C, most preferably at or about 5-0°C.

Preferably the formulations of the invention contain an antioxidant, such as  
5 methionine, sodium bisulfite, salts of ethylenediaminetetraacetic acid (EDTA),  
butylated hydroxytoluene (BHT), and butylated hydroxy anisole (BHA). Most  
preferred is methionine. The antioxidant prevents oxidation of FSH and LH  
(particularly the  $\alpha$ -subunit).

10 Methionine in the liquid and/or reconstituted formulation is preferably present at a  
concentration of at or about 0.01 to at or about 1.0 mg/ml, more preferably at or  
about 0.05 to at or about 0.5 mg/ml, most preferably at or about 0.1 mg/ml.

15 Preferably the formulations of the invention contain a mono - or disaccharide or a  
sugar alcohol as stabiliser and tonicity adjusting agent, such as sucrose, dex trose,  
lactose, mannitol and/or glycerol. Most preferred is sucrose, preferably at a  
concentration of at or about 60 mg/ml.

20 As noted above, the invention provides liquid formulations for single use and multi-  
dose use, containing a bacteriostatic, or to which a bacteriostatic is added when the  
formulation is reconstituted. The formulations of the invention are suitable for  
pharmaceutical or veterinary use.

25 As noted above, in a preferred embodiment, the invention provides an article of  
manufacture, comprising packaging material and a vial comprising a solution of FSH  
or an FSH variant, LH, or FSH and LH, Pluronic F68 and a bacteriostatic selected  
from phenol and *m*-cresol, optionally with buffers and/or other excipients, in an  
aqueous diluent, wherein said packaging material comprises written material which  
indicates that such solution may be held over a period of twenty-four hours or greater  
30 after the first use. The invention further comprises an article of manufacture,  
comprising packaging material, a vial comprising a formulation of FSH or an FSH  
variant according to the invention, wherein said packaging material comprises written  
material which instructs a patient to reconstitute the FSH or an FSH variant in the  
aqueous diluent to form a solution which may be held over a period of twenty-four  
35 hours or greater.

As noted above, in a preferred embodiment, the invention provides an article of manufacture, comprising packaging material and a vial comprising freeze dried FSH or an FSH variant, LH or an LH variant, or FSH and LH, Pluronic F68. The bacteriostatic within the second container including the diluent is selected from phenol and *m*-cresol, optionally with further excipients, wherein said packaging material comprises written material which indicates that such solution may be held over a period of twenty-four hours or greater after the first use.

The range of protein hormone in the formulations of the invention includes amounts yielding upon reconstitution, concentrations from about 1.0 µg/ml to about 50 mg/ml, although lower and higher concentrations are operable and are dependent on the intended delivery vehicle, e.g., solution formulations will differ from transdermal patch, pulmonary, transmucosal, or osmotic or micro pump methods. The protein hormone concentration is preferably at or about 5.0 µg/ml to at or about 2 mg/ml, more preferably at or about 10 µg/ml to at or about 1 mg/ml, most preferably at or about 50 µg/ml to at or about 200 µg/ml.

The range of protein hormone in the formulations of the invention includes amounts yielding upon reconstitution, concentrations from about 1.0 µg/ml to about 50 mg/ml, although lower and higher concentrations are operable and are dependent on the intended delivery vehicle, e.g., solution formulations will differ from transdermal patch, pulmonary, transmucosal, or osmotic or micro pump methods. The protein hormone concentration is preferably at or about 5.0 µg/ml to at or about 2 mg/ml, more preferably at or about 10 µg/ml to at or about 1 mg/ml, most preferably at or about 50 µg/ml to at or about 200 µg/ml.

Preferably the formulations of the invention retain at least at or about 80% of the FSH activity and/or LH activity at the time of packaging over a period of 24 months (before the first use). FSH activity can be measured using the Steelman-Pohley ovarian weight gain bioassay<sup>5</sup>. LH activity can be measured using the rat seminal vesicle weight gain bioassay.

The liquid formulations of the present invention can be prepared by a process which comprises mixing FSH or an FSH variant, LH, or a mixture of FSH and LH and Pluronic F68 and a bacteriostatic selected from phenol and *m*-cresol as solids or dissolving FSH or an FSH variant, LH, or a mixture of FSH and LH ("protein") and

Pluronic F68 and a bacteriostatic selected from phenol and *m*-cresol in an aqueous diluent. Mixing the components and dissolving them in an aqueous diluent is carried out using conventional dissolution and mixing procedures. To prepare a suitable formulation, for example, a measured amount of FSH or FSH variant, LH or a mixture of FSH and LH in buffered solution is combined with Pluronic F68 and a bacteriostatic selected from phenol and *m*-cresol in a buffered solution in quantities sufficient to provide the protein, Pluronic F68 and the bacteriostatic at the desired concentrations. The resulting solution is then dispensed into vials, ampoules or cartridges. Variations of this process would be recognized by one of ordinary skill in the art. For example, the order the components are added, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that may be optimised for the concentration and means of administration used.

15 In a preferred embodiment, the liquid formulations of the invention are made by preparing individual stock solutions of known concentration of all the components of the formulation (e.g. buffer sodium phosphate, sucrose, TWEEN, methionine, FSH and/or LH), and aliquoting volumetric amounts to form a "mother solution" of the same composition as the final formulation. The "mother solution" is preferably filtered through a Duropore® (Millipore) 0.22 micron PDF membrane, to remove microorganisms, and then aliquots are dispensed into individual containers, such as vials, ampoules or cartridges.

The freeze dried formulations of the present invention can be prepared by a process which comprises mixing FSH or an FSH variant, LH or an LH variant, or a mixture of FSH and LH and Pluronic F68 as well as further excipients like an antioxidant and/or a buffer and subjecting the mixture to a lyophilisation. Mixing the components and lyophilising them is carried out using conventional procedures. To prepare a suitable formulation, for example, a measured amount of FSH or FSH variant, LH or LH variant or a mixture of FSH and LH is combined with Pluronic F68 and the resulting mixture is lyophilized and then dispensed into vials, ampoules or cartridges. Variations of this process would be recognized by one of ordinary skill in the art. For example, the order the components are added, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that may be optimised for the concentration and means of administration used.

The formulations of the invention can be administered using recognized devices. Examples comprising these single vial systems include pen-injector devices for delivery of a solution such as EasyJect®, Gonal-F® Pen, Humaject®, NovoPen®, B-D®Pen, AutoPen®, and OptiPen®.

5       The products presently claimed include packaging material. The packaging material provides, in addition to the information required by the regulatory agencies, the conditions under which the product may be used. The packaging material of the present invention provides instructions to the patient to reconstitute the FSH or an  
10      FSH variant in the aqueous diluent to form a solution and to use the solution over a period of twenty-four hours or greater for the two vial, wet/dry, product. For the single vial, solution product, the label indicates that such solution may be stored after first use for a period of twenty-four hours or greater, preferably for up to 12 or 14 days.  
The presently claimed products are useful for human pharmaceutical product use.

15      15      The stable preserved formulations may be provided to patients as clear solutions. The solution may be for single use or it may be reused multiple times and may suffice for a single or multiple cycles of patient treatment and thus provides a more convenient treatment regimen than currently available.

20      20      FSH or an FSH variant, LH, or mixtures of FSH and LH in either the stable or preserved formulations or solutions described herein, may be administered to a patient in accordance with the present invention via a variety of delivery methods including SC or IM injection; transdermal, pulmonary, transmucosal, implant, osmotic  
25      25      pump, cartridge, micro pump, oral, or other means appreciated by the skilled artisan, as well-known in the art.

30      The following examples are provided merely to further illustrate the preparation of the formulations and compositions of the invention. The scope of the invention shall not be construed as merely consisting of the following examples.

**Example 1****Comparative formulations****Materials**

Item	Manufacturer
r-hFSH Bulk used for candidate formulations	Laboratoires Serono SA
D-Mannitol (DAB, Ph Eur, BP, FU, USP, FCC, E421)	Merck
Sucrose (DAB, Ph Eur, BP, NF)	Merck
NaCl (ACS, ISO)	Merck
Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O (GR for analysis)	Merck
NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O (GR for analysis)	Merck
Benzyl Alcohol (GR for analysis)	Merck
<i>m</i> -Cresol (for synthesis)	Merck
TWEEN 20 (Polysorbate 20) (for synthesis)	Merck
Pluronic F68 (Poloxamer 188)	Sigma
<i>l</i> -Methionine (for biochemistry)	Merck
Ortho-phosphoric Acid 85% (Ph Eur, BP, NF)	Merck
1.5 mL glass cartridge	SFAM (siliconed at Aguettant)
Rubbers Type A	West Company
Crim caps	Aguettant
Millex-GV	Millipore
Syringe Driven Filter Unit – Durapore	
Durapore Membrane Filters 0.22 µm GV	Millipore
20 mL Plastic syringe Plastipak	Becton Dickinson
Steel Holder for filtration	Sartorius

**Equipment**

HPLC Systems	Detector mod. 486 or 490 Controller mod. 600S Pump mod. 626 Autosampler mod. 717	Waters	2
pH meter	Mod. 654	Metrohm	1
Osmometer	030-D	Osmomat	1

5 The following study evaluated the following parameters for a large number of formulations:

- Compatibility of surfactant and bacteriostatic
- Oxidation of alpha-subunit

10 The formulations were multi-dose formulations and contained either TWEEN 20 or Pluronic F68 as well as a bacteriostatic agent. The following three bacteriostatic agents were evaluated:

- Benzyl alcohol 0.9%
- *m*-Cresol 0.3%
- Phenol 0.5%

15

TWEEN 20 and Pluronic F68 were used at the following range of concentrations:

- TWEEN 20 : range from 10 to 100 µg/g
- Pluronic F68 : range from 10 to 100 µg/g

20 Solutions prepared are listed in Table 1.

Table 1: Comparative formulations

ID #	$\text{Na}_2\text{HPO}_4$	$\text{NaH}_2\text{PO}_4$	r-HFSH*	Pluronic F68	TWEEN 20	Bacteriostat	Excipient (mg/g)
	2H <sub>2</sub> O (mg/g)	H <sub>2</sub> O (mg/g)		( $\mu\text{g/g}$ )	( $\mu\text{g/g}$ )		
1P	1.11	0.45	600 IU/g	10	-	0.5% Phenol	Sucrose 70.6
2P	1.11	0.45	600 IU/g	10	-	0.5% Phenol	Mannitol 38.7
3P	1.11	0.45	600 IU/g	100	-	0.5% Phenol	Sucrose 70.6
4P	1.11	0.45	600 IU/g	100	-	0.5% Phenol	Mannitol 38.7
5P	1.11	0.45	600 IU/g	-	10	0.5% Phenol	Sucrose 70.6
6P	1.11	0.45	600 IU/g	-	10	0.5% Phenol	Mannitol 38.7
7	1.11	0.45	600 IU/g	-	100	0.9% benzyl alcohol	NaCl 6.0
8	1.11	0.45	600 IU/g	-	100	0.9% benzyl alcohol	Sucrose 62.3
9	1.11	0.45	600 IU/g	-	100	0.9% benzyl alcohol	Mannitol 34.1

Table 1: Comparative Formulations

ID #	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O (mg/g)	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O (mg/g)	r-HFSH* 600 IU/g	Pluronic F68 (µg/g)	TWEEN 20 (µg/g)	Bacteriostat: 0.3% m- Cresol	Excipient NaCl 7.6
10	1.11	0.45	-	-	100	0.3% m- Cresol	NaCl 7.6
11	1.11	0.45	600 IU/g	-	100	0.3% m- Cresol	Sucrose
12	1.11	0.45	600 IU/g	-	100	0.3% m- Cresol	78.0
13	1.11	0.45	600 IU/g	-	10	0.3% m- Cresol	Mannitol 42.7
14	1.11	0.45	600 IU/g	-	10	0.9% benzyl alcohol	NaCl 6.0
15	1.11	0.45	600 IU/g	-	10	0.9% benzyl alcohol	Sucrose 62.3
16	1.11	0.45	600 IU/g	-	10	0.9% benzyl alcohol	Mannitol 34.1
17	1.11	0.45	600 IU/g	-	10	0.3% m- Cresol	NaCl 7.6
18	1.11	0.45	600 IU/g	-	10	0.3% m- Cresol	Sucrose 78.0
							Mannitol 42.7

Table 1: Comparative Formulations

ID #	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O (mg/g)	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O (mg/g)	r-hIFSH <sup>a</sup> 600 IU/g	Pluronic F68 (µg/g)	TWEEN 20 (µg/g)	Bacteriostat: 0.9% benzyl alcohol	Excipient NaCl 6.0
19	1.11	0.45	600 IU/g	100	-	0.9% benzyl alcohol	Sucrose
20	1.11	0.45	600 IU/g	100	-	0.9% benzyl alcohol	Sucrose
21	1.11	0.45	600 IU/g	100	-	0.9% benzyl alcohol	Mannitol
22	1.11	0.45	600 IU/g	100	-	0.9% benzyl alcohol	34.1
23	1.11	0.45	600 IU/g	100	-	0.3% m- Cresol	NaCl 7.6
24	1.11	0.45	600 IU/g	100	-	0.3% m- Cresol	Sucrose
25	1.11	0.45	600 IU/g	10	-	0.9% benzyl alcohol	78.0
26	1.11	0.45	600 IU/g	10	-	0.3% m- Cresol	Mannitol
27	1.11	0.45	600 IU/g	10	-	0.9% benzyl alcohol	42.7

Table 1: Comparative formulations

ID #	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O (mg/g)	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O (mg/g)	r-hFSH* 600 IU/g	Pluronic F68 (µg/g)	TWEEN 20 (µg/g)	Bacteriostat: Cresol	Excipient NaCl 7.6
28	1.11	0.45	600 IU/g	10	-	-	0.3% m-
29	1.11	0.45	600 IU/g	10	-	Cresol	
30	1.11	0.45	600 IU/g	10	-	Cresol	Sucrose 78.0
					-	0.3% m-	Mannitol 42.7

\*FSH was added to the formulations on the basis of its biopotency instead of protein content.

From visual examination of the formulations, it was determined that TWEEN 20 cannot be used with *m*-cresol and phenol because FSH formulations containing TWEEN 20 and *m*-cresol or TWEEN 20 and phenol presented a white opalescent suspension. In contrast, FSH formulations containing Pluronic F68 did not exhibit this problem with *m*-cresol and phenol. The use of Pluronic F68 permits the use of phenol and *m*-cresol.

**Combination of FSH and Pluronic F68 with antioxidants**

10 The following antioxidants were evaluated for their ability to inhibit oxidation of the  $\alpha$ -subunit in the presence of Pluronic F68:

- Methionine : range from 10 to 100  $\mu\text{g/g}$
- Ascorbic Acid : range from 10 to 100  $\mu\text{g/g}$

15 Sucrose and Mannitol were used as tonicity agents and TWEEN 20 or Pluronic were added at the concentration of 100  $\mu\text{g/g}$ .

The formulations prepared are listed in Table 2.

Table 2. Comparative formulations with and without methionine

ID#	$\text{Na}_2\text{HPO}_4$	$\text{NaH}_2\text{PO}_4$	RifSH	Pluronics	TWEEN	Ascorbic Acid	Methionine (kg/g)	Bacteriostat	Excipient
	2 $\text{H}_2\text{O}$ (mg/g)	$\text{H}_2\text{O}$ (mg/g)		F68 (kg/g)	(kg/g)	(kg/g)			
31	1.11	0.45	600 IU/g	100	-	-	-	0.3% m-cresol	Sucrose
32	1.11	0.45	600 IU/g	100	-	-	-	0.3% m-cresol	Mannitol
33	1.11	0.45	600 IU/g	-	100	-	-	0.9% benzyl alcohol	Sucrose
34	1.11	0.45	600 IU/g	-	100	-	-	0.9% benzyl alcohol	Mannitol
35	1.11	0.45	600 IU/g	100	-	-	-	0.9% benzyl alcohol	Sucrose
36	1.11	0.45	600 IU/g	100	-	-	-	0.9% benzyl alcohol	Mannitol
37	1.11	0.45	600 IU/g	100	-	-	-	0.9% benzyl alcohol	Sucrose
38	1.11	0.45	600 IU/g	100	-	-	-	0.3% m-cresol	Mannitol
39	1.11	0.45	600 IU/g	100	-	-	100	0.3% m-cresol	Sucrose

Table 2. Comparative formulations with and without methionine

ID#	$\text{Na}_2\text{HPO}_4$	$\text{NaH}_2\text{PO}_4$	RhFSH	Puronic F68	TWEEN (μg/g)	Ascorbic Acid (μg/g)	Methionine (μg/g)	Bacteriostat	Excipient
40	1.11	0.45	600 IU/g	100	-	-	100	0.3% m-cresol	Mannitol
41	1.11	0.45	600 IU/g	100	-	-	100	0.3% m-cresol	Sucrose
42	1.11	0.45	600 IU/g	100	-	10	-	0.3% m-cresol	Mannitol
43	1.11	0.45	600 IU/g	100	-	10	-	0.3% m-cresol	Sucrose
44	1.11	0.45	600 IU/g	100	-	100	-	0.3% m-cresol	Mannitol
45	1.11	0.45	600 IU/g	-	100	-	10	0.9% benzyl alcohol	Sucrose
46	1.11	0.45	600 IU/g	-	100	-	10	0.9% benzyl alcohol	Mannitol
47	1.11	0.45	600 IU/g	-	100	-	100	0.9% benzyl alcohol	Sucrose
48	1.11	0.45	600 IU/g	-	100	-	100	0.9% benzyl alcohol	Mannitol

Table 2. Comparative formulations with and without methionine

ID#	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O (mg/g)	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O (mg/g)	RifFSH	Pluronic F68 (μg/g)	TWEEN (μg/g)	Ascorbic Acid (μg/g)	Methionine (μg/g)	Bacteriostat	Excipient
49	1.11	0.45	600 IU/g	-	100	10	-	0.9% benzyl alcohol	Sucrose
50	1.11	0.45	600 IU/g	-	100	10	-	0.9% benzyl alcohol	Mannitol
51	1.11	0.45	600 IU/g	-	100	100	-	0.9% benzyl alcohol	Sucrose
52	1.11	0.45	600 IU/g	-	100	100	-	0.9% benzyl alcohol	Mannitol
53	1.11	0.45	600 IU/g	100	-	-	10	0.9% benzyl alcohol	Sucrose
54	1.11	0.45	600 IU/g	100	-	-	10	0.9% benzyl alcohol	Mannitol
55	1.11	0.45	600 IU/g	100	-	-	100	0.9% benzyl alcohol	Sucrose
56	1.11	0.45	600 IU/g	100	-	-	100	0.9% benzyl alcohol	Mannitol
57	1.11	0.45	600 IU/g	100	-	10	-	0.9% benzyl alcohol	Sucrose

Table 2. Comparative formulations with and without methionine

ID#	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O (mg/g)	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O (mg/g)	RhFSH	Pluronic F58 (μg/g)	TWEEN (μg/g)	Ascorbic Acid (μg/g)	Methionine (1mg/g)	Bacteriostat	Excipient
58	1.11	0.45	600 IU/g	100	-	10	-	0.9% benzyl alcohol	Mannitol
59	1.11	0.45	600 IU/g	100	-	100	-	0.9% benzyl alcohol	Sucrose
60	1.11	0.45	600 IU/g	100	-	100	-	0.9% benzyl alcohol	Mannitol
61	1.11	0.45	600 IU/g	100	-	100	-	0.9% benzyl alcohol	Sucrose
62	1.11	0.45	600 IU/g	100	-	-	-	Phenol	Mannitol
63	1.11	0.45	600 IU/g					Phenol	Mannitol
64	1.11	0.45	600 IU/g					Phenol	Sucrose
65	1.11	0.45	600 IU/g	100	-	-	10	Phenol	Mannitol
66	1.11	0.45	600 IU/g	100	-	-	100	Phenol	Sucrose
67	1.11	0.45	600 IU/g	100	-	-	100	Phenol	Mannitol
68	1.11	0.45	600 IU/g	100	-	10	-	Phenol	Sucrose
69	1.11	0.45	600 IU/g	100	-	100	-	Phenol	Mannitol
70	1.11	0.45	600 IU/g	100	-	100	-	Phenol	Sucrose

FSH was added to the formulations on the basis of its biopotency instead of protein content.

20 g of each formulation was prepared into Falcon polypropylene tubes and filtered through a 3cm<sup>2</sup> 0.22 µm Millex-GV Syringe Driven filter unit Durapore, then analysed for a value at t=0. The solutions were then stored at 40°C and tested according the following scheme:

Analytical test	T=0	1 week	2 weeks	3 weeks	4 weeks
Reverse Phase-HPLC for oxidised alpha subunit (%)	X	X	X	X	X
Size Exclusion-HPLC for protein quantitation (µg/g)	X	X	X	X	X
Size Exclusion-HPLC for qualitative free subunits	X	X	X	X	X

5

(X) : Test performed

Reverse phase HPLC reveals that in formulations containing FSH, Pluronic F68, *m*-cresol and methionine (at 10 and 100 µg/ml), oxidation of the α-subunit of FSH when the formulation is stored at 40°C, is greatly reduced, versus a formulation containing no methionine, as can be seen in Figure 1. Based on the average of two experiments, in the formulation containing no methionine, the percent of oxidised α-subunit is 2.3 at T=0, 4.0 at T= 1 week, and 7.1 at T= 2 weeks. In the formulation containing 10 µg/ml methionine, the percent of oxidised α-subunit is 2.0 at T=0, 3.2 at T= 1 week, and 3.8 at T= 2 weeks. In the formulation containing 100 µg/ml methionine, the percent of oxidised α-subunit is 1.8 at T=0, 1.7 at T= 1 week, and 1.3 at T= 2 weeks.

#### Example 2

20 Liquid single-dose formulation of recombinant FSH for subcutaneous or  
Intramuscular injection

Based on the results of Example 1, the following formulation was prepared.

Components 1 to 7 listed in Table 3 were prepared as volumetric solutions in WFI. Aliquots of each solution were added to a mixing vessel to form a "mother solution".  
25 The mother solution was dispensed into vials to contain 10.9 micrograms (150 IU) or 5.45 micrograms (75 IU) of FSH.

With recombinant FSH, the bioactivity and specific activity are consistent, allowing the FSH to be filled by mass, rather than by bioassay.

**Table 3. Components of FSH single dose liquid formulations**

Component #	Description	150 IU FSH	75 IU FSH
1	rhFSH ( $\mu$ g/vial)	10.9 (150 IU)	5.45 (75 IU)
2	Sucrose (mg/vial)	15.00	7.50
3	$\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ (mg/vial)	0.111	0.0555
4	$\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ (mg/vial)	0.273	0.1365
5	Pluronic F68 (mg/vial)	0.025	0.0125
6	Methionine (mg/vial)	0.025	0.0125
7	<i>m</i> -cresol (mg/vial)	0.75	0.375
8	PH	7.0	7.0
9	WFI	q.s. to 1 ml	q.s. to 0.5 ml

5 The vials were filled and sealed under sterile conditions. The formulation has a shelf life of up to two years at ambient temperatures.

**Example 3**

**Liquid multi-dose formulation of recombinant FSH for subcutaneous or  
10 intramuscular injection**

Based on the results of Example 1, the following multi-dose formulation was prepared.

Components 1 to 7 listed in Table 4 were prepared as volumetric solutions in WFI.

15 Aliquots of each solution were added to a mixing vessel to form a "mother solution". The mother solution was dispensed into vials to contain 22.2 micrograms (305 IU), 33.3 micrograms (458 IU) and 66.7 micrograms (916 IU) of FSH. The resulting formulations deliver a total of 300, 450 and 900 IU of FSH.

20 The cartridges were filled and sealed under sterile conditions. The multi-dose formulation can be stored at or about 2-8°C, more preferably at or about 4-5°C, until the first use for up to two years. After the first use, the cartridge should be

stored at or about 2-8°C, more preferably at or about 4-5°C, over the multi-dose period, which may be 24 hours, 2 days, or up to 12 or 14 days.

**Table 4. Components of FSH multi-dose liquid formulations**

Component #	Description	300 IU FSH	450 IU FSH	900 IU FSH
1	rhFSH (µg/cartridge)	22.2 (305 IU)	33.3 (458 IU)	66.7 (916 IU)
2	Sucrose (mg/cartridge)	30.0	45.0	90.0
3	NaH <sub>2</sub> PO <sub>4</sub> ·H <sub>2</sub> O (mg/cartridge)	0.225	0.337	0.675
4	Na <sub>2</sub> HPO <sub>4</sub> ·2H <sub>2</sub> O (mg/cartridge)	0.555	0.832	1.665
5	Pluronic F68 (mg/vial)	0.050	0.075	0.150
6	Methionine (mg/vial)	0.050	0.075	0.150
7	<i>m</i> -cresol (mg/vial)	1.50	2.25	4.50
8	pH	7.0	7.0	7.0
9	WFI	q.s. to 0.5 ml	q.s. to 0.75 ml	q.s. to 1.5 ml

5   **Example 4**

**Liquid single-dose formulation of recombinant LH for subcutaneous or intramuscular injection**

The following formulation was prepared.

10   Components 1 to 7 listed in Table 5 were prepared as volumetric solutions in WFI. Aliquots of each solution were added to a mixing vessel to form a "mother solution". The mother solution was dispensed into vials to contain 3 micrograms (75 IU) of LH. The resulting formulation delivers a single dose of 75 IU LH.

15   With recombinant LH, the bioactivity and specific activity are consistent, allowing the LH to be filled by mass, rather than by bioassay.

Table 5. Components of LH single dose liquid formulation		
Component #	Description	LH 75 IU
1	rhLH (µg/vial)	3.0
2	Sucrose (mg/vial)	52.5
3	NaH <sub>2</sub> PO <sub>4</sub> ·H <sub>2</sub> O (mg/vial)	0.052
4	Na <sub>2</sub> HPO <sub>4</sub> ·2H <sub>2</sub> O (mg/vial)	0.825
5	Pluronic F68 (mg/vial)	0.0125
6	Methionine (mg/vial)	0.125
7	<i>m</i> -cresol (mg/vial)	0.375
9	WFI	q.s. to 0.5 ml

The vials were filled and sealed under sterile conditions. The formulation has a shelf life of up to two years.

5

#### Example 5

#### Liquid multi-dose formulations of recombinant FSH and LH (2:1) for subcutaneous or intramuscular injection

The following multi-dose formulations of FSH and LH were prepared, with FSH:LH ratio of 2:1.

Components 1 to 8 listed in Table 6 were prepared as volumetric solutions in WFI. Aliquots of each solution were added to a mixing vessel and mixed to form a "mother solution". The pH of the mother solution was adjusted to 8.0, if necessary, by addition of NaOH or HCl. The mother solution was dispensed into cartridges to contain 18.3 micrograms LH (457 IU) with 66.7 micrograms FSH (916 IU), intended for 6 doses of 150 IU FSH each; 9.2 micrograms LH (230 IU) with 33.3 micrograms FSH (458 IU), intended for 3 doses of 150 IU FSH each; and 6.1 micrograms LH (152.5 IU) with 22.23 micrograms FSH (305 IU), intended for 2 doses of 150 IU FSH each.

The cartridges were filled and sealed under sterile conditions. The multi-dose formulation can be stored at or about 2-8°C, more preferably at or about 4-5°C until

the first use for up to two years. After the first use, the cartridge should be stored at at or about 2-8°C, more preferably at or about 4-5°C, over the multi-dose period, which may be 24 hours, 2 days, or up to 12 or 14 days.

Table 6. Components of FSH and LH (2:1) multi-dose liquid formulations				
Component #	Description	6 doses	3 doses	2 doses
1	rhLH (µg/cartridge)	18.3 (457 IU)	9.2 (230 IU)	6.1 (152.5 IU)
2	rhFSH (µg/cartridge)	66.7 (916 IU)	33.3 (458 IU)	22.23 (305 IU)
3	Sucrose (mg/cartridge)	115.5	57.75	38.5
4	H <sub>3</sub> PO <sub>4</sub> (mg/cartridge)	1.35	0.735	0.49
5	NaOH (mg/cartridge)	q.s. to pH 8.0	q.s. to pH 8.0	q.s. to pH 8.0
6	Pluronic F68 (mg/vial)	375.0	187.5	125.0
7	Methionine (µg/cartridge)	225	112.5	75.0
8	<i>m</i> -cresol (mg/cartridge)	4.5	2.25	1.5
9	pH	8.0	8.0	8.0
10	WFI	q.s. to 1.5 ml	q.s. to 0.75 ml	q.s. to 0.5 ml

5

#### Example 6

##### Liquid multi-dose formulations of recombinant FSH and LH (1:1) for subcutaneous or Intramuscular Injection

The following multi-dose formulations of FSH and LH were prepared, with FSH:LH ratio of 1:1.

Components 1 to 8 listed in Table 7 were prepared as volumetric solutions in WFI. Aliquots of each solution were added to a mixing vessel and mixed to form a "mother solution". The pH of the mother solution was adjusted to 8.0, if necessary, by addition of NaOH or HCl. The mother solution was dispensed into cartridges to contain 36.6 micrograms LH (914 IU) with 66.7 micrograms FSH (916 IU), intended

10

15

for 6 doses of 150 IU FSH each; 18.4 micrograms LH (460 IU) with 33.3 micrograms FSH (458 IU), intended for 3 doses of 150 IU FSH each; and 12.2 micrograms LH (305 IU) with 22.23 micrograms FSH (305 IU), intended for 2 doses of 150 IU FSH each.

5

The cartridges were filled and sealed under sterile conditions. The multi-dose formulation can be stored at or about 2-8°C, more preferably at or about 4-5°C until the first use for up to two years. After the first use, the cartridge should be stored at or about 2-8°C, more preferably at or about 2-8°C, more preferably at or about 4-5°C, 10 over the multi-dose period, which may be 24 hours, 2 days, or up to 12 or 14 days.

Table 7. Components of FSH and LH (1:1) multi-dose liquid formulations

Component #	Description	6 doses	3 doses	2 doses
1	rhLH (µg/cartridge)	36.6 (914 IU)	18.4 (460 IU)	12.2 (305 IU)
2	rhFSH (µg/cartridge)	66.7 (916 IU)	33.3 (458 IU)	22.23 (305 IU)
3	Sucrose (mg/cartridge)	115.5	57.75	38.5
4	H <sub>3</sub> PO <sub>4</sub> (mg/cartridge)	1.35	0.735	0.49
5	NaOH (mg/cartridge)	q.s. to pH 8.0	q.s. to pH 8.0	q.s. to pH 8.0
6	Pluronic F68 (mg/vial)	375.0	187.5	125.0
7	Methionine (µg/cartridge)	225	112.5	75.0
8	<i>m</i> -cresol (mg/cartridge)	4.5	2.25	1.5
9	pH	8.0	8.0	8.0
10	WFI	q.s. to 1.5 ml	q.s. to 0.75 ml	q.s. to 0.5 ml

**Example 7****Stability experiments for liquid multi-dose formulations of FSH mixed with LH****7.1. Reverse phase HPLC analysis for protein content**

The formulation of Example 5 (6 doses) was evaluated for protein content for both

5 FSH and LH, using a reverse-phase HPLC method.

Protein content (FSH and LH) was measured at zero time, and after 1, 2, 3 and 6 months storage of the formulation at 4°C. The results are listed in Table 8 as micrograms of FSH or LH per gram of solvent.

10

**7.2. Assay of oxidised alpha-subunit**

The percentage of oxidised alpha-subunit in a formulation of Example 5 was measured by a reverse phase HPLC (RP-HPLC) method.

15

The percentage of oxidised alpha-subunit was measured at zero time, and after 1, 2, 3 and 6 months storage at 4°C. The results are listed in Table 8.

**7.3. In vivo assay for FSH**

The formulation of Example 5 (6 doses) was tested for FSH activity using the

20 Steelman-Pohley ovarian weight gain bioassay at zero time, and after 1, 2, 3 and 6 months of storage at 4°C. The results are listed in Table 8 as international units (IU) per gram of solvent.

**7.4. In vivo assay for LH**

25 The formulation of Example 5 (6 doses) was tested for LH activity using the rat seminal vesicle weight gain bioassay at zero time, and after 1, 2, 3 and 6 months of storage at 4°C. The results are listed in Table 8 as international units (IU) per gram of solvent.

**30 7.5. Evaluation of free subunit (rFSH + rLH)**

For a formulation of Example 5 the percentage of free subunit was evaluated by SDS-PAGE.

35 Measurements were made at zero time, and after 1, 2, 3 and 6 months storage at 4°C. The results are reported as a percentage of the total protein (rFSH + rLH), and are listed in Table 8.

#### 7.5. Evaluation of aggregates

For a formulation of Example 5, the percentage of aggregates was evaluated by SDS-PAGE as described above for evaluation of free subunit in 7.5., except that higher molecular weight aggregates were determined as a percentage of the total protein (rFSH + rLH). Measurements were made at zero time and after 1, 2, 3 and 6 months storage at 4°C. Results are listed in Table 8.

#### 7.6. Visible particles

The formulation of Example 5 was evaluated visually for particles at zero time, and after 3 and 6 months of storage at 4°C. Results are reported in Table 8.

#### 7.7. pH

The pH of a formulation of Example 5 was measured at zero time and after 1, 2, 3 and 6 months storage at 4°C. Results are listed in Table 8.

15

**Table 8. Analytical parameters for a liquid formulation of FSH and LH (2:1) at zero time and after storage at 4°C for 1, 2, 3 and 6 months**

Assay	Zero time	1 month	2 months	3 months	6 months
rFSH content by RP-HPLC (micrograms/g)	46.50	46.98	46.71	46.31	44.98
rLH content by RP-HPLC (micrograms/g)	11.74	11.81	12.68	12.67	13.21
% alpha-subunit oxidised	2.29	2.17	2.08	2.48	2.95
In vivo assay for FSH 553(IU/g)	566	Not tested	Not tested	Not tested	578 (23 weeks)
In vivo assay for LH (IU/g)	331	Not tested	Not tested	311	286
SDS-PAGE free subunit (rFSH + rLH; %)	≤ 5	Not tested	Not tested	≤ 5	≤ 5 (23 weeks)
SDS-PAGE aggregates (rFSH + rLH; %)	≤ 2	Not tested	Not tested	> 3	4
Visible particles	Free	Not tested	Not tested	Free	Free
pH	8.262	8.215	8.216	8.188	8.283

**Example 8****FSH and LH freeze dried multidose formulation**

Two freeze dried formulations A and B having the following compositions have been prepared:

**5 Formulation A**

	FSH	µg 32.75 (450 I.U.)
	LH	µg 9.0 (225 I.U.)
	Sucrose	mg 15.0
	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O	mg 0.052
10	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O	mg 0.825
	Pluronic F-68	mg 0.05
	L-Methionine	mg 0.05

**Formulation B**

	FSH	µg 65.5 (900 I.U.)
15	LH	µg 18.0 (450 I.U.)
	Sucrose	mg 30.0
	NaH <sub>2</sub> PO <sub>4</sub> H <sub>2</sub> O	mg 0.104
	Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O	mg 1.65
	Pluronic F68	mg 0.10
20	L-Methionine	mg 0.10

The manufacturing process consists in mixing the drug substance directly with the ingredients, filtrating the solution obtained and lyophilising the filtrated.

A description of each step of the process is given in the following :

- add in a tared container WFI, di-sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate monohydrate, Sucrose, Pluronic F68 at 5% and L-methionine and stir for 10 minutes until complete dissolution.
- check the pH and eventually correct it to pH 7.00 ± 0.2 with NaOH 10% or diluted H<sub>3</sub>PO<sub>4</sub>.
- add FSH and LH to the above prepared mixture and gently stir the solution obtained for 10 minutes.
- check the pH again and eventually adjust it to 7.0 ± 0.1 with 10% NaOH or diluted H<sub>3</sub>PO<sub>4</sub>.

- filter the solution with a 0.22 µm Durapore membrane with a filtration ratio not less than 15g/cm<sup>2</sup>, under Nitrogen gas flow with a pressure not higher than 1.5 atm.
- collect the solution in a previously sterilised flask.

5 - fill the filtered solution into the glass container, seat the stopper and place the filled vials into a stainless steel tray.

- load the trays into the freeze dryer and lyophilise the product using the following freeze drying cycle :
  - equilibrate at +4°C for about 20 mins.
  - bring the shelves temperature at -25°C and maintain for 2 hours.
  - bring the shelves temperature at -15°C and maintain for 1 hour.
  - bring the shelves temperature at -45°C and maintain for 3 hours.
  - bring condenser temperature at -65°C.
  - apply vacuum to the chamber.

10 15 When the vacuum reaches a value of  $7 \times 10^{-2}$  mBar raise shelf temperature up to -10°C and maintain for 14 hours.

- raise the shelf temperature up to +35°C in 8 hours and maintain up to the end of the cycle (14 hours).
- break the vacuum allowing dry nitrogen into the chamber.

15 20 perform the stoppering by automatic system of the freeze dryer.

- seal the stoppered vials with the appropriate flip-off caps.

The formulations A and B have been stored at 25 ± 2°C, and tested for stability and biological activity as pointed out below. Prior to analysing the compositions, they are reconstituted using water for injection comprising 0.3% of m-Cresol as bacteriostatic agent.

The stability and biological activity values were determined as follows :

- In vivo assay for FSH : The formulation was tested for FSH activity using the Steelman-Pohley ovarian weight gain bioassay
- In vivo assay for LH : The formulation was tested for LH activity using the rat seminal vesicle weight gain bioassay.
- Assay of oxidised alpha-subunit : The percentage of oxidised alpha-subunit was measured by a reverse phase HPLC (RP-HPLC) method.
- Evaluation of free subunit (rFSH + rLH) : The percentage of free subunit was evaluated by SDS-PAGE.

- Evaluation of aggregates : The percentage of aggregates was evaluated by SDS-PAGE as described above for evaluation of free subunit.

The biological tests have been performed in compliance with the regulations of the European Pharmacopoeia. In particular the tests are reported in the "Menotropin" monography.

Table 9 summarizes the results of the analytical tests related to stability and biological activity of formulation A. The values were determined at 4 check-points : at time zero, after 1 month, 3 months and 6 months of storage, at a storage temperature of  $25 \pm 2^\circ\text{C}$ .

10

TABLE 9

TEST	TIME ZERO	1 MONTHS	3 MONTHS	6 MONTHS
Biological activity I.U. FSH	416	420	415	417
Biological activity I.U. LH	276	250	269	270
% oxidised product	1.95	1.81	1.95	1.57
% dimers/aggregates	<2	<2	<2	<2
% free subunits	<5	<5	<5	<5

Table 10 summarizes the results of the analytical tests related to stability and biological activity of formulation B. The values were determined at 4 check-points : at time zero, after 3 month, 6 months and 9 months of storage, at a storage temperature of  $25 \pm 2^\circ\text{C}$ .

15

TABLE 10

TEST	TIME ZERO	3 MONTHS	6 MONTHS	9 MONTHS
Biological activity I.U. FSH	821	850	830	838
Biological activity I.U. LH	570	564	580	622
% oxidised product	1.0	0.9	1.0	1.0
% dimers/aggregates	<2	<2	<2	<2
% free subunits	<5	<5	<5	<5

From TABLE 9 and 10 it may be concluded that the biological activity of formulations A and B is well conserved after 9 months of storage. The formulations have a high stability.

20 The high stability is not affected by large amounts of recombinant FSH and recombinant LH.

**Sequences:**

SEQ ID NO. 1: human glycoprotein  $\alpha$ -subunit;  
SEQ ID NO. 2: hFSH  $\beta$ -subunit  
SEQ ID NO. 3: hFSH  $\beta$ -subunit variant 1  
5 SEQ ID NO. 4: hFSH  $\beta$ -subunit variant 2  
SEQ ID NO. 5: hFSH  $\beta$ -subunit variant 3  
SEQ ID NO. 6: hLH  $\beta$ -subunit

**References**

<sup>1</sup> Burgues et al.; *Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorion luteinizing hormone for the treatment of male hypogonadotropic hypogonadism*. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism ; *Hum. Reprod.*; 1997, 12, 980-6;

<sup>2</sup> Shome et al., *J. Clin. Endocrinol. Metab.* 39:187-205 (1974); Shome, et al., *J. Prot. Chem.*, 7:325-339, 1988;

<sup>3</sup> Keutmann et al.; *Structure of human luteinizing hormone beta subunit: evidence for related carboxyl-terminal sequence among certain peptide hormones* ; *Biochem. Biophys. Res. Commun.*; 1979, 90, 842-848; Talmadge et al. ; *Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone* ; *Nature*; 1984, 307, 37-40; Fiddes & Talmadge; *Structure, expression, and evolution of the genes for the human glycoprotein hormones*; *Recent Prog. Horm. Res.*; 1984, 40, 43-78

<sup>4</sup> Reichert LE, Ramsey RB; *Dissociation of human follicle -stimulating hormone*; *J. Biol. Chem.*; 1975, 250, 3034-3040

<sup>5</sup> Klein et al.; *Pharmacokinetics and pharmacodynamics of single -chain recombinant human follicle-stimulating hormone containing the human chorionic gonadotrophin carboxyterminal peptide in the rhesus monkey*; *Fertility & Sterility*; 2002, 77, 1248-1255

<sup>6</sup> a) Fiddes, J.C., et al., *J of Mol. and Applied Genetics*, 1:3-18(1981); b) Esch F.S., et al. *DNA* 5:363-369(1986); c) Watsons P.C., et al., *DNA* 6:205-212(1987); d) Hirai T., et al., *J. Mol. Endocrinol.* 5:147-158(1990); e) Maurer, R.A., et al., *Mol. Endocrinol.* 1:717 -723(1987); f) Guzman K., et al., *DNA Cell Biol.* 10:593 -601(1991); g) Kumar TR, et al., *Gene*. 1995 Dec 12;166(2):335-6; h) Kumar TR, et al., *Gene*. 1995 Dec 12;166(2):333 -4

<sup>7</sup> Biochem. Biophys. Res. Commun.; 1979, 90, 842-848

<sup>8</sup> Steelman et al.; *Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotrophin*; *Endocrinology*; 1953, 53, 604 -616

<sup>9</sup> Van Heij et al.; *Effects of human menopausal gonadotrophin preparations in different bioassay methods*; *Acta Endocrinologica*; 1964, 47, 409-418

<sup>10</sup> Van Heij et al.; *Effects of human menopausal gonadotrophin preparations in different bioassay methods*; *Acta Endocrinologica*; 1964, 47, 409-418

**Claims**


1. A liquid pharmaceutical composition comprising follicle-stimulating hormone (FSH) or a variant thereof, as well as a surfactant selected from Pluronic® F77, 5 Pluronic F87, Pluronic F88 and Pluronic F68.
2. A liquid pharmaceutical composition comprising follicle-stimulating hormone (FSH) or a variant and luteinising hormone (LH) or a variant thereof, as well as a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and 10 Pluronic F68.
3. A liquid pharmaceutical composition comprising luteinising hormone (LH) or a variant thereof, as well as a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.
- 15 4. A liquid pharmaceutical composition according to any of the preceding claims, wherein the follicle-stimulating hormone (FSH) is present at a concentration of at or about 150 IU/ml to at or about 1'200 IU/ml.
5. A liquid pharmaceutical composition according to claim 4, wherein the 20 follicle-stimulating hormone (FSH) is present at a concentration of at or about 300 IU/ml to at or about 900 IU/ml.
6. A liquid pharmaceutical composition according to claim 5, wherein the 25 follicle-stimulating hormone (FSH) is present at a concentration of at or about 600 IU/ml.
7. A liquid pharmaceutical composition according to any of claims 2 or 3, wherein the luteinising hormone (LH) is present at a concentration of at or about 150 30 IU/ml to at or about 1'200 IU/ml.
8. A liquid pharmaceutical composition according to claim 7, wherein the luteinising hormone (LH) is present at a concentration of at or about 300 IU/ml to at or about 750 IU/ml.

9. A freeze-dried formulation comprising follicle-stimulating hormone (FSH) or a variant thereof, as well as a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.
10. A freeze-dried formulation comprising luteinising hormone (LH) or a variant thereof, as well as a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.
11. A freeze-dried formulation comprising follicle-stimulating hormone (FSH) or a variant thereof as well as luteinising hormone (LH) or a variant thereof, as well as a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.
12. The freeze dried formulation according to any of claims 9 to 11, wherein the follicle-stimulating hormone (FSH) is present at a concentration (w/w) of at or about 0.1 to 10 µg/mg of the total formulation.
13. The freeze dried formulation according to claim 12, wherein the follicle-stimulating hormone (FSH) is present at a concentration of at or about 0.3 to 5 µg/mg of the total formulation.
14. The freeze dried formulation according to claim 13, wherein the follicle-stimulating hormone (FSH) is present at a concentration of at or about 0.37 to 2 µg/mg of the total formulation.
15. The freeze dried formulation according to any of claims 9 to 11, wherein the luteinising hormone (LH) is present at a concentration of at or about 0.1 to 3 µg/mg of the total formulation.
16. The freeze dried formulation according to claim 15, wherein the luteinising hormone (LH) is present at a concentration of at or about 0.1 to 1 µg/mg of the total formulation.
17. The freeze dried formulation according to claim 16, wherein the luteinising hormone (LH) is present at a concentration of at or about 0.1 to 0.6 µg/mg of the total formulation.
18. A pharmaceutical composition according to any of claim 1 to 17, wherein the surfactant is Pluronic F68.

19. A pharmaceutical composition according to any of the preceding claims, wherein the follicle-stimulating hormone is human follicle-stimulating hormone and/or the luteinising hormone (LH) is human luteinising hormone (LH).  
5
20. A pharmaceutical composition according to claim 19, wherein the follicle-stimulating hormone is urinary human follicle-stimulating hormone and/or the luteinising hormone (LH) is urinary human luteinising hormone (LH).
- 10 21. A pharmaceutical composition according to claim 19, wherein the follicle-stimulating hormone is recombinant human follicle-stimulating hormone and/or the luteinising hormone (LH) is recombinant human luteinising hormone (LH).
- 15 22. A pharmaceutical composition according to any of the preceding claims, wherein the ratio of FSH to LH is within the range of at or about 6:1 to at or about 1:6.
- 20 23. A pharmaceutical composition according to claim 22, wherein the ratio of FSH to LH is within the range of at or about 4:1 to at or about 1:2.
24. A pharmaceutical composition according to claim 23, wherein the ratio of FSH to LH is within the range of at or about 3:1 to at or about 1:1.
- 25 25. A pharmaceutical composition according to claim 24, wherein the ratio of FSH to LH is within the range of at or about 2:1 and 1:1.
26. A pharmaceutical composition according to any of the preceding claims, further comprising a bacteriostatic agent selected from phenol and *m*-cresol.
- 30 27. A pharmaceutical composition according to claim 26, wherein the bacteriostatic agent is *m*-cresol.
28. A pharmaceutical composition according to claim 27, comprising *m*-cresol at a concentration of at or about 0.3% (mass/mass solvent).

29. A pharmaceutical composition according to any of the preceding claims, further comprising sucrose.
30. A pharmaceutical composition according to any of the preceding claims, further comprising methionine.
31. A pharmaceutical composition according to any of the preceding claims, further comprising a phosphate buffer at a pH of at or about 6.0 to at or about 8.0.
- 10 32. A pharmaceutical composition according to claim 31, further comprising a phosphate buffer at a pH of at or about 7.0.
33. A pharmaceutical composition according to claim 32, comprising the following ingredients: rFSH, Pluronic F68, sucrose, methionine, *m*-cresol, and an aqueous phosphate buffer at a pH of at or about 7.0.
- 15
34. A pharmaceutical composition according to claim 33, wherein the rFSH is present at a concentration of at or about 600 IU/ml, the Pluronic F68 is present at a concentration of at or about 0.1 mg/ml, the sucrose is present at a concentration of at or about 60 mg/ml, the methionine is present at a concentration of at or about 0.1 mg/ml, the *m*-cresol is present at a concentration of at or about 3 mg/ml, and the phosphate buffer is at or about 20 10 mM in phosphate.
35. A freeze dried formulation according to claim 11, comprising 32.75 µg of recombinant FSH, 9.0 µg of recombinant LH, 15.0 mg of sucrose, 0.052 mg of NaH<sub>2</sub>PO<sub>4</sub> H<sub>2</sub>O, 0.825 mg of Na<sub>2</sub>HPO<sub>4</sub> 2H<sub>2</sub>O, 0.05 mg of Pluronic F68 and 0.05 mg of L-methionine.
- 25
36. The freeze dried formulation according to claim 11, comprising 65.5 µg of recombinant FSH, 18.0 µg of recombinant LH, 30.0 mg of sucrose, 0.104 mg of NaH<sub>2</sub>PO<sub>4</sub> H<sub>2</sub>O, 1.65 mg of Na<sub>2</sub>HPO<sub>4</sub> 2H<sub>2</sub>O, 0.10 mg of Pluronic F68 and 0.10 mg of L-methionine.
- 30
37. A method for manufacturing a pharmaceutical composition comprising the step of forming a solution of FSH, and a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and a liquid diluent.

38. A method according to claim 37, wherein the surfactant is Pluronic F68.
39. A method according to claim 37 or 38, comprising the further step of adding a bacteriostatic agent selected from phenol and *m*-cresol.  
5
40. A method for manufacturing a packaged pharmaceutical composition comprising placing a solution comprising FSH, and a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, in a vial, ampoule or cartridge.
- 10 41. A method according to claim 40, wherein the surfactant is Pluronic F68.
42. An article of manufacture comprising a first container filled with a freeze dried formulation according to any claims from 9 to 11 and a second container comprising a solvent for reconstitution.
- 15 43. An article of manufacture according to claim 42, whereby the second container comprises an aqueous diluent containing *m*-cresol.
44. A method for manufacturing a freeze dried formulation according to any of claims 9 to 11, comprising the step of forming a mixture of FSH with or without LH, or LH alone/LH as well as a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68, and subjecting the mixture to a  
20 lyophilisation.
45. A method according to claim 44, wherein the surfactant is Pluronic F68.

**Figure 1**

## SEQUENCE LISTING

<110> ARES TRADING SA

<120> FSH and FSH variant formulations

<130> US 847 Y

<160> 6

<170> PatentIn version 3.1

<210> 1

<211> 91

<212> PRT

<213> Homo sapiens

<400> 1

Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro  
1 5 10 15

Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys  
20 25 30

Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu  
35 40 45

Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser  
50 55 60

Tyr Asn Arg Val Thr Val Met Gly Gly Phe Val Glu Asn His Thr Ala  
65 70 75 80

Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser  
85 90

<210> 2

<211> 129

<212> PRT

<213> Homo sapiens

<400> 2

Met Lys Thr Leu Gln Phe Phe Phe Leu Phe Cys Cys Trp Lys Ala Ile  
1 5 10 15

Cys Cys Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys  
20 25 30

Glu Glu Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly  
35 40 45

Tyr Cys Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys  
50 55 60

Ile Gln Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg  
65 70 75 80

Val Pro Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val  
85 90 95

Ala Thr Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys  
100 105 110

Thr Val Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met Lys  
115 120 125

Glu

<210> 3

<211> 108

<212> PRT

<213> Homo sapiens

<400> 3

Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu

1                   5                   10                   15

Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys  
20                   25                   30

Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln  
35                   40                   45

Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg Val Pro  
50                   55                   60

Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr  
65                   70                   75                   80

Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val  
85                   90                   95

Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu  
100                   105

<210> 4

<211> 106

<212> PRT

<213> Homo sapiens

<400> 4

Asn Ser Cys Glu Leu Thr Asn Ile Ala Ile Glu Lys Glu Glu Cys Arg  
1                   5                   10                   15

Phe Cys Ile Ser Ile Asn Thr Trp Cys Ala Gly Tyr Cys Tyr Thr Arg  
20                   25                   30

Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln Lys Thr Cys  
35                   40                   45

Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg Val Pro Gly Cys Ala  
50                   55                   60

His His Ala Asp Ser Leu Tyr Thr Val Pro Val Ala Thr Gln Cys His  
65                   70                   75                   80

Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu  
85                   90                   95

Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met  
100 105

<210> 5

<211> 110

<212> PRT

<213> Homo sapiens

<400> 5

Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu  
1 5 10 15

Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys  
20 25 30

Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln  
35 40 45

Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg Val Pro  
50 55 60

Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr  
65 70 75 80

Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val  
85 90 95

Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met Lys  
100 105 110

<210> 6

<211> 112

<212> PRT

<213> Homo sapiens

<400> 6

Ser Arg Glu Pro Leu Arg Pro Trp Cys His Pro Ile Asn Ala Ile Leu  
1 5 10 15

Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr  
20 25 30

Ile Cys Ala Gly Tyr Cys Pro Thr Met Arg Val Leu Gln Ala Val Leu  
35 40 45

Pro Pro Leu Pro Gln Val Cys Thr Tyr Arg Asp Val Arg Phe Glu Ser  
50 55 60

Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asp Pro Val Val Ser Phe  
65 70 75 80

Pro Val Ala Leu Ser Cys Arg Cys Gly Pro Cys Arg Arg Ser Thr Ser  
85 90 95

Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr Cys Asp His Pro Gln  
100 105 110

**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - a sequence listing
    - table(s) related to the sequence listing
  - b. format of material
    - in written format
    - in computer readable form
  - c. time of filing/furnishing
    - contained in the international application as filed
    - filed together with the international application in computer readable form
    - furnished subsequently to this Authority for the purpose of search
2.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations.

The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/050432

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K47/10 A61K38/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, MEDLINE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 974 359 A (LILLY CO ELI) 26 January 2000 (2000-01-26) cited in the application paragraphs '0014! - '0020! paragraph '0025! paragraphs '0074! - '0076! paragraph '0081!; example 12 paragraph '0083! paragraph '0125! ----- EP 0 853 945 A (AKZO NOBEL NV) 22 July 1998 (1998-07-22) cited in the application page 3, lines 51,52 page 4, lines 23-37 -----	1-45
Y		1-45 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 August 2004

Date of mailing of the international search report

13/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Deck, A

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/050432

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 811 096 A (ALEMAN CLAUDE ET AL) 22 September 1998 (1998-09-22) column 1, lines 47-52 column 2, lines 30-51 column 3, lines 5-42	1-45
Y	----- US 6 066 620 A (CHANG C PAUL ET AL) 23 May 2000 (2000-05-23) column 1, lines 26-60 column 3, lines 53-55 column 6, lines 18-24 column 16, lines 25-34; claims 1-3	1-45
Y	----- EP 0 318 081 A (AKZO NV) 31 May 1989 (1989-05-31) examples	1-45
Y	----- FR 2 782 455 A (SANOFI SA) 25 February 2000 (2000-02-25) page 2, lines 1-25 page 4, lines 3-14; claim 10	1-45
Y	----- EP 0 603 159 A (GENENTECH INC) 22 June 1994 (1994-06-22) claims	1-45
Y	----- EP 0 448 146 A (AKZO NV) 25 September 1991 (1991-09-25) cited in the application page 4, line 31 - page 5, line 27; examples	1-45
Y	----- US 5 650 390 A (SAMARITANI FABRIZIO ET AL) 22 July 1997 (1997-07-22) cited in the application the whole document	1-45
A	----- US 5 356 876 A (ESPEY LAWRENCE L) 18 October 1994 (1994-10-18) the whole document	1-45
A	----- GB 1 065 127 A (SERONO IST FARM) 12 April 1967 (1967-04-12) the whole document	1-45

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2004/050432

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0974359	A	26-01-2000	AT 228850 T AU 4998099 A BR 9912243 A CA 2335340 A1 CN 1309567 T DE 69904262 D1 DE 69904262 T2 DK 974359 T3 EP 1188444 A1 EP 0974359 A2 ES 2183486 T3 HK 1026615 A1 ID 28747 A JP 2002521342 T NO 20010326 A NZ 508874 A PL 346127 A1 PT 974359 T SI 974359 T1 WO 0004913 A1 US 2003166525 A1 US 2002165146 A1 ZA 200100190 A	15-12-2002 14-02-2000 16-10-2001 03-02-2000 22-08-2001 16-01-2003 24-07-2003 03-03-2003 20-03-2002 26-01-2000 16-03-2003 24-10-2003 28-06-2001 16-07-2002 20-03-2001 26-03-2004 28-01-2002 28-02-2003 30-04-2003 03-02-2000 04-09-2003 07-11-2002 08-01-2002
EP 0853945	A	22-07-1998	EP 0853945 A1 EP 1285665 A1 AT 237348 T AU 736339 B2 AU 5205998 A BR 9800323 A CA 2226803 A1 CN 1191139 A CZ 9800135 A3 DE 69813322 D1 DE 69813322 T2 DK 853945 T3 ES 2196474 T3 HK 1010150 A1 HU 9800056 A2 ID 19499 A JP 10203997 A NO 980177 A NZ 329572 A PL 324279 A1 PT 853945 T RU 2203086 C2 TR 9800062 A2 TW 518235 B US 5929028 A ZA 9800083 A	22-07-1998 26-02-2003 15-05-2003 26-07-2001 23-07-1998 29-06-1999 15-07-1998 26-08-1998 12-08-1998 22-05-2003 19-02-2004 04-08-2003 16-12-2003 25-07-2003 28-08-1998 16-07-1998 04-08-1998 16-07-1998 28-05-1999 20-07-1998 29-08-2003 27-04-2003 21-08-1998 21-01-2003 27-07-1999 08-07-1998
US 5811096	A	22-09-1998	FR 2733914 A1 AU 5213996 A CA 2175971 A1 CN 1147961 A , B CZ 9601350 A3 EA 960024 A2 EP 0742013 A1	15-11-1996 21-11-1996 12-11-1996 23-04-1997 11-12-1996 31-12-1996 13-11-1996

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2004/050432

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 5811096	A		GR 3031896 T3 HU 9601241 A2 IL 118171 A JP 2950775 B2 JP 9025242 A NO 961915 A NZ 286554 A PL 314147 A1 SG 42355 A1 AT 183925 T AU 710288 B2 BR 1100337 A3 DE 69604009 D1 DE 69604009 T2 DK 742013 T3 ES 2137635 T3 SI 742013 T1 TW 420614 B ZA 9603683 A	29-02-2000 28-04-1997 31-08-2000 20-09-1999 28-01-1997 12-11-1996 24-09-1998 12-11-1996 15-08-1997 15-09-1999 16-09-1999 25-07-2000 07-10-1999 06-04-2000 06-03-2000 16-12-1999 31-12-1999 01-02-2001 10-11-1997
US 6066620	A	23-05-2000	US 5955427 A US 5696090 A US 5488034 A US 6255284 B1 AT 206308 T AU 695125 B2 AU 6133094 A CA 2155005 A1 CN 1127992 A DE 69428521 D1 DE 69428521 T2 DK 682524 T3 EP 0682524 A1 ES 2164098 T3 HK 1014156 A1 JP 10513433 T PT 682524 T WO 9417819 A1	21-09-1999 09-12-1997 30-01-1996 03-07-2001 15-10-2001 06-08-1998 29-08-1994 18-08-1994 31-07-1996 08-11-2001 23-05-2002 28-01-2002 22-11-1995 16-02-2002 17-04-2003 22-12-1998 28-03-2002 18-08-1994
EP 0318081	A	31-05-1989	AT 65410 T AU 2579188 A CA 1317899 C DE 3863908 D1 DK 648088 A EP 0318081 A1 ES 2051830 T3 GR 3002971 T3 IE 60719 B1 JP 1168624 A MX 165991 B NZ 227088 A US 4902500 A ZA 8808577 A	15-08-1991 01-06-1989 18-05-1993 29-08-1991 28-05-1989 31-05-1989 01-07-1994 25-01-1993 10-08-1994 04-07-1989 14-12-1992 26-07-1990 20-02-1990 30-08-1989
FR 2782455	A	25-02-2000	FR 2782455 A1 AT 230258 T AU 5173699 A DE 69904727 D1	25-02-2000 15-01-2003 14-03-2000 06-02-2003

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2004/050432

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
FR 2782455	A		DE 69904727 T2 DK 1105102 T3 EP 1105102 A1 ES 2189456 T3 WO 0010534 A1 PT 1105102 T SI 1105102 T1	13-11-2003 22-04-2003 13-06-2001 01-07-2003 02-03-2000 30-04-2003 31-08-2003
EP 0603159	A	22-06-1994	US 5096885 A EP 0603159 A2 AT 112685 T AU 627174 B2 AU 3368789 A CA 1329543 C DE 68918853 D1 DE 68918853 T2 EP 0409870 A1 JP 2747073 B2 JP 3503764 T NZ 228747 A WO 8909614 A1 US 5763394 A US 2003013653 A1 US 2001007858 A1	17-03-1992 22-06-1994 15-10-1994 20-08-1992 03-11-1989 17-05-1994 17-11-1994 13-04-1995 30-01-1991 06-05-1998 22-08-1991 25-09-1991 19-10-1989 09-06-1998 16-01-2003 12-07-2001
EP 0448146	A	25-09-1991	AT 107172 T AU 631730 B2 AU 7362391 A CA 2037884 A1 DE 69102465 D1 DE 69102465 T2 DK 448146 T3 EP 0448146 A1 ES 2057731 T3 FI 911309 A HK 1002494 A1 ID 905 B IE 910732 A1 JP 3031570 B2 JP 4217630 A KR 221123 B1 NZ 237458 A PT 97074 A , B US 5384132 A US 5270057 A ZA 9101659 A	15-07-1994 03-12-1992 26-09-1991 21-09-1991 21-07-1994 02-03-1995 24-10-1994 25-09-1991 16-10-1994 21-09-1991 28-08-1998 10-09-1996 25-09-1991 10-04-2000 07-08-1992 15-09-1999 25-02-1992 31-10-1991 24-01-1995 14-12-1993 24-12-1991
US 5650390	A	22-07-1997	IT 1250075 B AT 189608 T AU 677773 B2 AU 3266293 A CA 2124801 A1 DE 69230672 D1 DE 69230672 T2 DK 618808 T3 EP 0618808 A1 ES 2142860 T3 GR 3033276 T3	30-03-1995 15-02-2000 08-05-1997 19-07-1993 24-06-1993 16-03-2000 21-09-2000 15-05-2000 12-10-1994 01-05-2000 29-09-2000

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP2004/050432

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 5650390	A		WO 9311788 A1 JP 7507047 T PT 618808 T	24-06-1993 03-08-1995 31-07-2000
US 5356876	A	18-10-1994	AU 3423693 A CA 2128017 A1 EP 0623027 A1 JP 7507050 T WO 9313799 A1	03-08-1993 22-07-1993 09-11-1994 03-08-1995 22-07-1993
GB 1065127	A	12-04-1967	FR 3819 M NL 6402059 A	14-09-1964